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CHAPTER 1 
GENERAL INTRODUCTION 
Partly based on: 
Bodeutsch C, De Wilde PCM, Kater L, Hené RJ, 
Van Den Hoogen FHJ, Van De Putte LBA, Vooijs GP: 
Labial salivary gland biopsy in Sjogren's syndrome. 
Neth J Med 40:148-156, 1992 
reprinted with permission 
Copyright 1992 by Elsevier Science Publishers B.V. 
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General introduction 
Definition 
Sjogren's syndrome (SS) is a systemic chronic autoimmune exocrinopathy, which 
affects in particular the lacrimal and salivary glands, giving rise to keratoconjunctivitis 
sicca (KCS) and xerostomia [1,2,3]. A division has been made in primary and secondary 
SS, depending on the presence of a coexisting connective tissue disease or systemic 
autoimmune disease [1]. 
Diagnosis 
Current tests for the evaluation of ocular and oral involvement in SS are rather 
non-specific [4]. Combinations of several non-specific tests are, therefore, performed 
(Table 1). The five most used sets of criteria for diagnosis of SS are the California 
criteria of Fox et al. [5,6], the Copenhagen criteria of Manthorpe et al. [3,7], the Greek 
citeria of the group of Moutsopoulos [8], the Japanese criteria of Homma et al. [9] and 
the criteria of Daniels and Talal [10] (Table 1). These different criteria sets define 
different patient populations, as recently has been emphasized by Yamada et al. [11]. 
These authors studied a group of 123 SS patients defined by the Japanese criteria [9]. 
The great majority of these patients would not be classified as having SS on the basis of 
the California, Copenhagen or Greek criteria [11]. 
Histopathology 
Histopathology of labial salivary glands (LSGs), obtained by the horizontal 
incision procedure according to Greenspan et al. [12], has long been considered the most 
disease-specific and most sensitive single test in the diagnosis of SS [13-17]. Various 
grading systems have been introduced to quantify the extent of inflammation of the LSGs 
in SS [14,18,19]. In all these grading systems the lymphocytic focus, defined as an 
aggregate of at least 50 lymphocytes and histiocytes, plays a central role. The 
lymphocytic foci are often localized around or in the vicinity of the intralobular ducts; an 
example of a small paraductal lymphocytic focus is given in Figure 1. The term 
"lymphocytic focus score", defined as the number of lymphocytic foci per 4 mm2 of LSG 
tissue, was introduced to quantify the grade of sialadenitis. 
Chomette et al. [20] concluded from a clinicopathological and ultrastructural 
study that the extent of ductectasia of the intralobular ducts in LSGs is a better diagnostic 
criterion than the lymphocytic focus score. They introduced another grading system to 
classify LSG involvement, based on the extent of ductectasia, lymphocytic infiltration, 
fibrosis and acinar atrophy [20], but this grading system has not found acceptance in the 
literature. An example of an area with fibrosis, ductal hyperplasia with ductectasia, a 
diffuse lymphoplasmacytic infiltrate and a small paraductal lymphocytic focus in a LSG 
biopsy of a SS patient is given in Figure 2. 
The most widely used grading systems for quantification of the extent of LSG 
inflammation are those of Chisholm and Mason [18] (Table 2) and Tarpley et al. [19] 
(Table 3). No international agreement exists on how to diagnose SS in the LSG biopsy 
(Table 4). Despite this, Daniels and Talal [10] recently defined the oral component of 
SS as a lymphocytic adenitis of the LSGs with a lymphocytic focus score > 1; the 
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TABLE 1 
Methods for determination of salivary gland and ocular gland involvement in Sjogren's syndrome 
as given in the five international criteria sets. 
Criteria set Investigation of salivary 
gland invotvemenl 
Investigation of ocular 
involvement 
Laboratory evidence of a systemic 
autoimmune disease 
California 
[5,6] 
Copenhagen 
[3,71 
Greece 
[8] 
Japan 
[9] 
Daniels and 
Talal 
[10] 
Schirmer's test ( < 9 mm/5 mm) 
Increased staining with 
rose-bengal or fluorescein dye 
Schirmer-l test (< 10 mm/5 mm) 
Break-up time (< 10 s) 
van Bijsterveld score ( > 4 + ) 
Symptomatic xerostomia 
Decreased basal and stimulated 
salivary flow rate 
Lymphocytic focus score > 2 in 
lip biopsy 
Unstimulated whole sialometry 
(abnormal if < 1 5 ml/15 min) 
Salivary gland scintigraphy 
(abnormal if uptake or sponta-
neous secretion or secretion 
following citrous stimulation 
is diminished) 
Lymphocytic focus score > 1 in 
lip biopsy 
Subjective xerostomia Subjective dry eyes 
Parotid gland enlargement Schirmer's test (< 5 mm/5 mm) 
Stimulated parotid flow rate Slit lamp examination after 
(abnormal if < 1 ml/5 mm/gland) rose-bengal staining 
Lip biopsy > 2 + (Tarpley's scale) 
Decreased salivary secretion 
Recurrent or chronic salivary 
gland swelling of unknown 
aetiology 
Positive sialogram (diffuse 
nodular or globular shadows 
with diameter > 1 mm diffusely 
in lobules) 
> 1 periductal lymphocytic focus 
salivary glands 
Focus score > 1 in lip biopsy 
(after exclusion of areas with 
duct dilation, interstitial 
fibrosis and diffuse acinar 
atrophy) 
Schmner's test ( < 10 mm/5 mm) 
Positive rose-bengal test 
( + +, or more) 
Positive fluorescent test ( + ) 
> 1 periductal lymphocytic focus 
in lacrimal glands 
Examination of corneal and 
conjunctival staining with 
rose-bengal dye through slit 
lamp 
Reduced tear break-up time 
Unanaesthelized Schirmer's test 
(< 5 mm/5 mm) 
Positive RF (titre >l 160) or 
Positive ANA (titre > 1 160) or 
Positive anti-SS-A or anti-SS-B 
Not included 
Not included 
Not included 
In possible Sjogren's syndrome 
Hypergammaglobuhnaemia 
(polyclonal or monoclonal) 
Positive RF 
Positive ANA 
Positive anti-SS-A 
Positive anti-SS-B 
In the first column references are given in brackets. 
TABLE 2 
Histological grading system of minor salivary glands in Sjogren's syndrome according to 
Chisholm and Mason [18]. 
Grade Lymphocytes per 4 mm2 of salivary gland tissue 
0 Absent 
1 Slight infiltrate 
2 Moderate infiltrate or less than one focus 
3 One focus 
4 More than one focus 
Focus = an aggregate of 50 or more lymphocytes and histiocytes. 
11 
Fig. 1. A small paraductally localized lymphocytic focus in a labial salivary gland of a patient 
with Sjogren's syndrome. A lymphocytic focus is defined as an aggregate of at least 50 
lymphocytes and histiocytes. 
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Fig. 2. Part of a labial salivary gland of a Sjogren's syndrome patient with acinar atrophy, 
interstitial fibrosis, ductal hyperplasia and ductectasia. Furthermore, in the right upper part of the 
figure, a small paraductal lymphocytic focus, and in the left part of the figure a diffuse 
lymphoplasmacytic infiltrate. 
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TABLE 3 
Histological grading of minor salivary glands in Sjogren's syndrome according to Tarpley et al. 
[19]. 
Class 0 Nonna! 
Class 1 Round cell aggregates, composed of lymphocytes, 
(1 + ) plasma cells, and histiocytes 
1 or 2 aggregates (minimal infiltration) 
Class II More than 3 aggregates (multiple) of round cells 
(2 + ) per lobule 
Class III Diffuse lobular round-cell infiltration with 
(3 + ) partial destruction of acinar tissue with or 
without fibrosis, the predominant cell varying 
from the lymphocyte to the plasma cell 
Class IV Diffuse round-cell infiltrate with or without 
(4 + ) fibrosis destroying the lobular architecture 
completely 
Each aggregate = approximately 50 cells (lymphocytes, plasma cells, or histiocytes). 
TABLE 4 
Histological criteria for diagnosis of Sjogren's syndrome in the labial salivary gland (LSG) biopsy 
and importance in the international criteria sets. 
Criteria set Extent of inflammation in LSG tissue Importance 
California [5,6] ä 2 lymphocytic foci per 4 mm2 LSG tissue Prerequisite 
Copenhagen [3,7] > I lymphocytic focus per 4 mm2 LSG tissue No prerequisite 
Greece [8] ä 2 -*- on Tarpley's scale Prerequisite 
Japan [9) > 1 periductal lymphocytic focus in the LSG tissue No prerequisite 
Daniels and Talal [10] > 1 lymphocytic focus per 4 mm2 LSG tissue Prerequisite 
(after exclusions, see Table 1) 
In the first column references are given in brackets. 
lymphocytic foci in areas with duct dilatation, interstitial fibrosis and diffuse acinar 
atrophy must be excluded [10,13]. But, the latter exclusion criteria were not used by 
others to determine the focus score. Indeed, patients with SS often have focal 
lymphocytic adenitis of the LSGs with a lymphocytic focus score > 1 , and this criterion 
has been proven to be useful to distinguish between SS and sarcoidosis [21]. However, in 
up to 74% of SS patients reported in scientific publications, a lymphocytic focus score 
> 1 was not present in the LSG biopsy [18,22-28]. The large discrepancies in sensitivity 
of the focus score > 1 criterion is mainly caused by differences in the selection criteria 
which were used to define the SS patients in the different studies. On the other hand, a 
lymphocytic focus score > 1 has been described in up to 10% of healthy individuals 
[29,30], in 18% of patients with systemic connective tissue diseases [31], in 36% of 
patients with myasthenia gravis [32], and also in patients with primary biliary cirrhosis 
[33], graft versus host disease [34], and acquired immunodeficiency syndrome [35,36]. 
This list of disorders which may be accompanied by a grade IV adenitis (focus score 
> 1 , see Table 2) of the LSGs clearly demonstrates the low specifity of the lymphocytic 
focus score criterion. 
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Epimyoepithelial islands, consisting of proliferating myoepithelial cells and 
intercalated duct cells, are rather specific for SS in the major salivary glands [37], but 
occur very rarely in LSGs [38]. When epimyoepithelial islands are present in the LSG 
tissue together with multinucleate giant cells, the differential diagnosis with sarcoidosis 
may be very difficult [39]. In these cases immunohistologic staining for muramidase may 
reveal the correct diagnosis, as epithelioid cells contain muramidase whereas the cells in 
the epimyoepithelial islands do not contain this enzyme [39]. 
To solve the problem of the rather low diagnostic yield of LSG biopsy in SS, 
when applying grading systems of lymphocytic infiltration, replacement of minor salivary 
gland biopsy by incisional parotid gland biopsy has been suggested [25]. Other 
investigators proposed a procedure including both LSG biopsy and sublingual salivary 
gland biopsy [28]. However, Wise et al. [27] concluded that findings from parotid gland 
biopsy added very little to those of the LSG biopsy. They found a significantly higher 
sensitivity of 67% for the LSG biopsy, while only 32% of parotid gland biopsies showed 
evidence of SS [27]. 
Histomorphometry 
Various quantitative microscopic studies have indicated that changes in the LSGs 
which are usually seen in SS such as fibrosis, ductectasia, diffuse acinar atrophy and 
lymphocytic infiltrates, can also occur in the glands of healthy individuals, partly due to 
the physiologic aging process [30,40,41]. Therefore, Daniels [13] proposed to exclude 
areas with these non-specific changes in LSGs in the determination of the lymphocytic 
focus score. 
The histological differences in the LSGs of 20 patients with SS and 68 healthy 
control subjects have been assessed in a quantitative microscopic study, including 10 
histomorphometric parameters [42,43]. This histomorphometric study has convincingly 
demonstrated that ductal changes, acinar atrophy and interstitial fibrosis cannot be 
exclusively considered to be age-related regressive alterations. But, they are an essential 
part of the histological changes in the LSGs in SS, as demonstrated earlier by Chomette 
et al. [20]. A stepwise linear discriminant analysis performed on the 10 
histomoiphometric parameters resulted in a diagnostic criterion for SS, based on the 5 
best discriminating parameters and an overall correction term for age-dependent changes 
of these parameters [43]. These 5 histomorphometric parameters are: the ratio of the 
inner- and outer-diameter of intralobular ducts and the volume percentages of intralobular 
ducts, acini, bloodvessels and diffuse lymphoplasmacytic infiltrate. This 
histomorphometric diagnostic criterion for SS has a specificity of 97% and a sensitivity 
of 95%. In spite of these excellent classification results, this diagnostic criterion for SS is 
not attractive to implement in daily diagnostic practice, because histomorphometric 
measurements are very time consuming and require a thorough knowledge of salivary 
gland histopathology. 
Immunologic disturbances 
Polyclonal B-cell activation, characterized by hypergammaglobulinemia and 
autoantibody formation is a common finding in patients with SS [1,2,3,44,45]. In 1970, 
Talal et al. [22] showed that lymphoid cells infiltrating LSGs of SS patients secreted 
large amounts of IgG, IgM, and Ig A. Subsequently, increased numbers of IgG- and IgM-
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containing plasma cells were demonstrated in LSGs of patients with SS [46] and in 
parotid glands of patients with chronic myoepithelial sialadenitis, a condition which is 
closely related to SS [47]. It was also demonstrated that LSGs of patients with SS are a 
site of rheumatoid factor production [23,48]. 
Autoantibodies directed to the La(SSB) antigen are very common in patients with 
SS [49,50,51,52]. They are found in the serum of 60-90% of patients with primary SS, 
30-50% of patients with secondary SS, 25-50% of patients with systemic lupus 
erythematosus, but rarely in the serum of patients with other connective tissue diseases 
[49,50,51,52]. It has been shown recently that saliva of patients with SS is enriched with 
anti-La(SSB) antibody compared to the serum [53]. Moreover, anti-La(SSB) antibody has 
been found in saliva of SS patients without detectable anti-La(SSB) antibody in the serum 
[53]. These findings suggest the production of anti-La(SSB) antibody in salivary glands 
of SS patients. The demonstration of anti-La(SSB) antibodies in the cytoplasm of plasma 
cells in LSG tissue of SS' patients, using antibodies against private idiotypes of anti-
La(SSB), further supports this suggestion [54]. However, it is still unclear whether the 
La(SSB) antigen and autoantibodies directed to this antigen play a role in the 
pathogenesis of SS. 
Various other immunologic disturbances have been demonstrated in LSGs of SS 
patients such as glandular HLA-DR expression [55,56,57], increased CD4/CD8 ratio 
[58,59], presence of CD5-positive B-cells [60], absence of natural killer cells [61], and 
the presence of large numbers of B-cells expressing the cross reactive idiotype recognized 
by monoclonal antibody 17-109 [62]. However, the concrete diagnostic possibilities of 
these immunologic abnormalities in LSGs have never been assessed. As SS is generally 
considered to be an autoimmune exocrinopathy, the study of local immunologic 
disturbances within the LSGs is probably more appropriate for obtaining more sensitive 
and disease-specific criteria for this disorder than the rather non-specific histologic 
features. 
Quantitative immunohistology 
In 1989, De Wilde et al. [63] formulated a new diagnostic criterion for SS based 
on the local disturbances in the immunoglobulin production in LSG tissue. In their 
quantitative immunohistologic (QIH) study of LSG biopsies from 19 patients with SS and 
65 healthy control subjects they calculated a discriminant function (DF) which is based 
on the percentages of Ig A- and IgG-containing plasma cells in the LSG tissue [63]. Using 
their formula (DF = 0.062 χ %IgA - 0.088 χ %IgG - 4.387), the diagnosis of SS is 
reached if the outcome of the discriminant function (DF-score) is smaller than -1.19. The 
DF-score <-1.19 criterion has a specificity of 95.4% and a sensitivity of 100%. The 
excellent diagnostic possibilities of this bivariate immunohistologic criterion was further 
supported by another study [64]. This study disclosed that addition of the 3 best 
discriminating histomorphometric parameters, viz. the volume percentages of diffuse 
lymphoplasmacytic infiltrate, intralobular ducts and acini, to the percentages IgA- and 
IgG-containing plasma cells gave only a slightly higher specificity of 98.5%, instead of 
the 95.4% specificity of the DF-score <-1.19 criterion alone. 
Speight et al. [65] formulated another immunohistologic diagnostic criterion for 
SS based on the percentage of IgM-containing plasma cells in the LSG tissue. In the LSG 
biopsies studied by Speight et al. [65], more than 10% IgM-containing plasma cells was 
exclusively observed in patients with SS. 
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In both the study of De Wilde et al. [63] and that of Speight et al. [65] only 
small patient groups were used. Furthermore, to evaluate the specificity and the 
sensitivity of QIH criteria it needs to be established: 1) whether QIH criteria are able 
distinguish to the focal lymphocytic adenitis of LSGs in patients with connective tissue 
diseases from the focal adenitis in SS, and 2) whether QIH criteria are able to confirm 
the diagnosis SS in patients with KCS, but with a lymphocytic focus score < 1 in the 
LSG biopsy. Since various fixatives and immunohistologic staining methods are in use, it 
is of great importance to know the effect of these factors on the results of QIH 
examination. For application of QIH examination of LSG biopsies in daily diagnostic 
practice, interobserver reproducibility of the results of QIH examination must be 
warranted. 
Lymphoproliferative disease 
In some patients with SS the disease evolves into a systemic benign or malignant 
monoclonal B-cell lymphoproliferative process [66,67], mostly of the IgM/kappa type 
[68]. In fact, the relative risk of developing malignant lymphoma in patients with SS has 
been estimated to be about 44x higher than in the normal population [67]. Although a 
sudden decrease of serum immunoglobulin concentration has been recognized as a herald 
of malignant transformation [2,69,70], it is not possible to detect SS patients prone to 
such a transformation at the time of diagnosis of SS. In this respect the finding that 
development of non-Hodgkin lymphoma has been observed exclusive in those SS patients 
with myoepithelial sialadenitis of the major salivary glands showing monotypic B-cell 
proliferation areas [69] is very interesting. Furthermore, progression from a polyclonal 
into a monoclonal infiltrate within major salivary glands of patients with SS has been 
demonstrated [69]. In addition, with Southern blot studies immunoglobulin gene 
rearrangements indicating monoclonality have been demonstrated in major salivary glands 
of patients with SS [71,72]. However, the clinical relevance of these findings is limited, 
since the LSG biopsy is used much more commonly to diagnose SS than major salivary 
gland biopsy. In a recent study monoclonal plasma cell populations, defined by a 
kappa/lambda ratio greater than 3, were demonstrated in LSGs of more than 50% of SS 
patients with a coexisting monoclonal IgM/kappa cryoglobulinemia [73]. However, 
systematic studies on the prevalence of monotypia of the plasma cellular infiltrate in 
LSGs of SS patients without systemic monoclonal lymphoproliferative disorders at the 
time of LSG biopsy and the relation to progression into the latter disorders have never 
been published. 
Concluding remarks and scope of this thesis 
The results from the literature obviously indicate that immunohistologic 
examination of target organs (i.e. labial salivary glands) of patients with SS may provide 
valuable information for diagnosis, prognosis, and pathogenesis of this autoimmune 
exocrinopathy. 
A crucial question is whether tissue fixation and immunohistologic staining 
procedures influence the reliability and the inter-observer reproducibility of QIH 
diagnoses. This issue is studied in chapter 2. 
So far, only small and homogeneous patient groups have been used to study the 
diagnostic value of QIH examination of LSG biopsies in SS. In chapter 3 larger and 
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more heterogeneous patient groups were used to study this issue, addressing the questions 
whether QIH examination improves the diagnosis of SS in patients with KCS and in 
patients with rheumatoid arthritis. 
Monotypic plasma cell populations are known to occur in salivary glands of SS 
patients with coexisting systemic monoclonal gammopathy or malignant lymphoma. 
However, the prevalence of monotypia of the plasma cellular infiltrate in LSG biopsies 
of SS patients without coexisting systemic benign or malignant lymphoproliferative 
disease at the time of LSG biopsy, and its prognostic significance with regard to the 
development of systemic monoclonal lymphoproliferative disease are still not known. 
These issues are studied in chapter 4. 
Recent studies have demonstrated that salivary glands of patients with SS are a 
site of anti-La(SSB) production. In chapter 5 we searched for immunohistologic evidence 
of altered La(SSB) expression in labial salivary gland tissue of SS patients, which can 
support the model of a local antigen driven anti-La(SSB) response. 
Illustrative case reports are presented in chapters 6 and 7 to emphazise the 
diagnostic and prognostic value of QIH examination of LSG biopsies in SS. 
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Abstract 
Recently two highly sensitive and specific diagnostic criteria for Sjogren's syndrome, 
based on percentages of IgA-, IgG-, and IgM-containing plasma cells measured in 
immunohistologically stained labial salivary gland tissue have been described. The 
reliability of such criteria is dependent on the accuracy, precision and inter-observer 
reproducibility in plasma cell counting. The present study evaluates the effect of 
tissue fixation and immunohistological procedures on the aforementioned factors. 
Immunoglobulin (Ig)-contaming plasma cells in sections of lamellated submandibular 
salivary gland tissue, alternately Fixed in a 4% buffered formol solution or formol-
sublimate solution and stained with an indirect immunoperoxidase and unlabelled 
peroxidase anti-peroxidase (PAP) method respectively, were enumerated by three 
independent observers. Relative numbers of Ig-containing plasma cells appeared to 
be less sensitive for systematic errors due to tissue fixation and immunohistological 
procedure than absolute numbers of Ig-containing plasma cells. The best inter-
observer reproducibility of plasma cell counts was obtained in sections from formol 
sublimate fixed specimens stained according to the PAP procedure. 
Introduction 
Recently, two highly sensitive and specific quantitative diagnostic criteria for 
Sjogren's syndrome have been described [5,11]. The criterion of Speight et al. [11] has 
been based on the percentage of IgM-containing plasma cells in labial salivary gland 
tissue. De Wilde et al. [5] based their criterion on the percentages of IgA- and IgG-
containing plasma cells in labial salivary gland tissue. 
The reliability of such quantitative diagnostic criteria is determined to a 
considerable degree by the accuracy and precesión in plasma cell counting. The 
applicability in daily diagnostic practice is further dependent on the reproducibility of 
plasma cell counting by independent observers. The accuracy of plasma cell counting is a 
statistical measure for the bias of the estimated number of immunoglobulin (Ig)-
containing plasma cells. A bias is induced by a fixed over- or underestimation due to 
systematic errors in the measurement of the numbers of immunohistologically stained Ig-
containing plasma cells in fixed and paraffin embedded tissue specimens. The magnitude 
of the standard deviation of the measured numbers of Ig-containing plasma cells 
determines the precision in plasma cell counting. The precision of a measurement 
depends on the occurrence of random errors. Factors that can account for systematic 
errors in Ig-containing plasma cell counts include: the choice of the tissue fixative 
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[3,4,6-8]; the choice of the immunoperoxidase technique [1]; the use of protease 
digestion to unmask immunoreactive sites [9]; the dilution of primary antisera [2,10]; the 
thickness of paraffin sections [6]; and the method of measuring [10]. Random errors are 
caused, for instance, by variations in the pH of the fixative, fluctuations in time and 
temperature of fixation, incubation and protease digestion, differences in activity between 
the antiserum batches, and variations in the thickness of tissue sections. To the best of 
our knowledge, no quantitative studies have been performed to evaluate the effects of 
these different factors on the accuracy and precision in the measurement of the numbers 
of Ig-containing plasma cells. 
The aim of this study was to evaluate the systematic and random effects of two 
widely used fixatives (4% buffered formol and formol-sublimate) and two 
immunoperoxidase techniques (the indirect- and the peroxidase anti-peroxidase (PAP) -
technique) on the absolute and relative numbers of Ig-containing plasma cells in 
submandibular salivary glands as well as to assess the effects of these fixatives and 
immunoperoxidase techniques on inter-observer variations. 
Material and Methods 
Subjects. Submandibular salivary glands, removed from 4 patients suffering 
from chronic obstruction adenitis, were lamellated. Ten tissue blocks were taken from 
each gland and were alternately fixed in a 4% buffered formol (BF) solution or formol-
sublimate (FS) solution. BF was chosen because it is a widely used fixative for routine 
tissue fixation. FS was chosen because it has been shown to be a good fixative for 
immunohistological (IH) demonstration of cytoplasmatic Ig [3,4] and because it has been 
used in a previous quantitative IH study [5]. After fixation the tissue blocks were 
embedded in paraffin and 4 μ m sections were cut for IH staining. 
Immunohistochemistry. The design of this factorial experiment is schematically 
represented in Fig. 1. The intracellular Igs of the IgA-, IgG- and IgM-classes were 
demonstrated in serial sections obtained from the 10 tissue blocks by Stemberger's 
unlabelled PAP procedure and by an indirect immunoperoxidase (IIP) method [9,12]. The 
details of the IH procedures are given in Table 1. Single batches of all antisera were 
obtained from Dakopatts, Denmark. Appropriate specificity tests and controls were done 
[5]. 
Morphometry and tissue sampling. The numbers of Ig-containing plasma cells 
were measured with a conventional microscope with an eye piece graticule and drawing 
tube. Via this tube, the plasma cells were scored with the cursor of a commercially 
available semi-automatic image analyzing system (MOP-Videoplan, Kontron, Munich). 
Every scored plasma cell was stored as dot on the TV monitor of the MOP to avoid 
errors in plasma cell counting in areas with high numbers of Ig-containing plasma cells. 
The eyepiece graticule corresponded with 0.04 mm2 SSG tissue when a x40 neofluar 
objective (NA = 0.75) was used. 
The following six IH parameters were used to quantify the composition of the 
Ig-containing plasma cell population in the submandibular glands: the number of the IgA 
(N-IgA)-, IgG (N-IgG)-, and IgM (N-IgM)-containing plasma cells and the percentages of 
IgA- (%IgA)-, IgG- (%IgG)- and IgM- (%IgM)-containing plasma cells. The latter three 
were expressed as fractions of the total number of Ig-containing plasma cells given by 
(N-IgA + N-IgG + N-IgM). 
A summation average experiment, using sections of all 4 fixative/technique 
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combinations, revealed that the mean number of IgA- and IgG-containing plasma cells 
was stable after 30 systematically sampled test fields of 0.04 mm2 and the mean number 
PATIEMT ρπ Π Ί Γ7! ΓΗ 
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Fig. 1. Diagram of the factorial experiment with fixatives and techniques nested and the obser­
vers cross-classified: FS, formol-sublimate; BF, 4% buffered formol; "30 test fields of 0.04 mm2 
were sampled in the anti-IgA and anti-IgG incubated sections, and SO in the anti-IgM incubated 
sections. 
TABLE 1 
Immunoperoxidase procedures used in this study 
1. Dewaxing and rehydration 
2. Removing of mercury pigment by immersion in Lugol's iodine (S mm) 
3. Blocking of endogenous peroxidase in methanol containing 1 % hydrogen peroxide (30 mm) 
4. Preincubation wiih normal swine serum (20 mm) 
5. Incubation with diluted monospecific anlisera against IgA (1/3200), IgG (1/600) and IgM (1/3200) 
(Ih) 
6. Incubation with diluted swine anti-rabbit serum (1/20) (30 mm) 
7. Incubation with diluted rabbit PAP complex (1/800) (20 mm) 
8. Development of peroxidase with diammobenzidine and hydrogen peroxide (5 mm), intensified with 
C u S 0 4 (1 mm) 
9. Counterstam with Mayer's hematoxylin, dehydrate and mount m DPX In IIP procedure step 6 and 
7 of PAP technique are replaced by incubation with peroxidase labelled swine anti-rabbit serum (I ¡SO) 
(30 min), antisera were diluted in phosphate-buffered saline (pH 7 4) containing 1% bovine serum 
albumin, incubations at room temperature 
of IgM-containing plasma cells after 50 test fields. The systematic sampling procedure 
used in this study has been described elsewhere in detail [5]. Each section was 
independently scored by three observers (CB, HK, and GE). 
Statistics. The mean values of the IH parameters, obtained from sections of five 
tissue blocks, were used for statistical analyses. The systematic and random effects of the 
fixatives and IH staining techniques as well as the effect of the inter-observer variations 
on the six IH parameters were evaluated in an analysis of variance (ANOVA). 
In a four-factor factorial experiment with patients (P), fixatives (F), techniques 
(T), and observers (O) as factors, the mixed ANOVA model is given by: 
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Χ* = μ+Ρ^Ρ,+Τ^ΪΡχΡ^+ίΡχΤ^ + ίΡχΤ^ + ίΡχΡχΤ^+Ο,+Ε,μ (1) 
The main effects, Ρ and О, are random, and the main effects, F and T, are fíxed. The 
first and second order interaction terms are random effects. Since the fixatives and 
techniques are nested and the observers are cross classified, the nested ANOVA model 
can be derived from (1) and is given by: 
^ = μ+Ρ,+Ρ,,+Τ^+Ο,+Ε,ρ (2) 
with 
Ft = F^PXF), 
and 
Tp = Т
к
+(РхТ),
к
 + (РхТ)
л
 + (РхРхТ),
л
 (2a) 
The nested ANOVA model (2) was used to test whether the random fixative and random 
technique effects, and the effect of the inter-observer variations were statistically 
significant. The mean squares obtained from the nested ANOVA were also used to 
estimate the components of variance of X (<?(X)) and these components are given by: 
Ο ,Μιβω» " Гиши .» ^ИсЬшяи. > " oburvtr ^ d " ішніш] ( = ° «плг/· 
The F-statistics, obtained from the mean squares (MS) of the fixed main effect and the 
random interaction terms given in (2a), were used to test whether the systematic fixative 
and systematic technique effects on the IH parameters are statistically significant. The F-
statistics for the systematic fixative and technique effects are given by: 
¿ W = М5(Г)/М5(Лс^) and F^^ = М5(7)/М8(ЛсГ+ЛГ+ЛсЛ7) (3) 
Until now, the assumptions made in ANOVA were: equivalence of all fixation and 
technique combinations, interchangeability of fixation and technique and that the 
variances of F„ and 7V, are not dependent on fixative (/) and technique (Jt). 
The variances of O, and E^¡ are possibly dependent on the choice of the fixative 
and technique. To assess these possibilities and to select the most favourable 
fixative/technique combination, an ANOVA was performed on each of the 4 
fixative/technique combinations. 
Results 
Qualitative study. Slides from FS-fixed specimens were qualitatively better than 
slides from tissue fixed in BF; the intensity of positive staining showed less fluctuations 
and the positive plasma cell boundaries were more readily discernable. Background 
staining, occurring mainly in anti-IgG incubated slides, was higher in slides from BF-
fixed specimens than in slides from FS-fixed specimens. It was also more difficult to 
determine positivity in weakly staining cells in slides from tissue fixed in BF. HP-stained 
slides showed a higher background staining than PAP-stained slides. Figure 2 shows 
examples of FS fixed and PAP stained serial sections, revealed for Ig A, IgG, and IgM. 
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Fig. 2. Immunohistological detection of IgA- (A), IgG- (В), and IgM- (С) containing plasma cells 
in submandibular salivary gland tissue. A, Using antiserum to IgA: clustering of IgA-containing 
plasma cells around acini. B, In a consecutive section of the same patient, using antiserum to 
IgG: IgG-containing plasma cells are seen solitary and in small clusters. C, In a consecutive 
section of the same patient, using antiserum to IgM, solitary IgM-containing plasma cells 
scattered in the interstitium. (Formol sublimate fixation, peroxidase anti-peroxidase technique, 
DAB/hematoxylin-stained, original magnification χ 500.) 
Quantitative study. Statistically significant (P=0.01) systematic effects of 
fixation and IH technique were only observed in N-IgA (Table 2). The relative numbers 
of Ig-containing plasma cells (%IgA, %IgG, and %IgM) were not affected by systematic 
errors due to fixation and IH procedure (P>0.25) (Table 3). 
Statistically significant (P<0.05) random effects due to tissue fixation occurred 
in N-IgA, N-IgG, and N-IgM (Table 2). Statistically significant (P<0.008) random 
effects due to IH procedure occurred in N-IgG, %IgA, and %IgG (Tables 2 and 3). 
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Statistically significant (Ρ ^ 0.003) inter-observer variations were present in N-IgA and 
N-IgG (Table 2) as well as in %IgA, %IgG and %IgM (Table 3). Analysis of the 
components of variance disclosed that < 4 5 % of the total variances of the six IH 
parameters was due to biological variation between patients (Tables 2 and 3). The 
relative contribution of the random fixation effect to the total variance was greater than 
25% in four of the six IH parameters, namely N-IgA, N-IgM, %IgA, and %IgG (Tables 
2 and 3). 
With exception of %IgM, the relative contributions of the random fixation effect 
to the total variances of the IH parameters were greater than those of the random 
technique effect and the inter-observer variations (Tables 2 and 3). Futhermore, these 
tables revealed that the relative contribution of the unknown residual effects was greater 
than the relative contribution of the inter-observer variations for all six IH parameters. 
The following considerations based on the ANOVA results for the four possible 
fixation/staining combinations, which are summarized in Tables 4 and 5, are more 
explorative and descriptive in nature. The mean values of N-IgA, N-IgG, and N-IgM 
were higher in the FS-fixed specimens for both IPP and PAP technique. However, with 
exception of N-IgA, these differences could not be ascribed to statistically significant 
systematic fixative effects. Furthermore, for both fixation methods, the IIP technique 
resulted in higher values of N-IgA, N-IgG, and N-IgM. Only the higher N-IgA could be 
ascribed to a statistically significant systematic effect of the technique. 
Another striking difference between the two fixatives is that statistically 
significant inter-observer variations in the numbers of Ig-containing plasma cells were 
only observed in BF-fixed specimens. The relative contributions of the inter-observer 
variations to the total variance in the numbers of Ig-containing plasma cells were smaller 
then 10% in FS-fixed specimens, while the relative contributions to the total variance of 
N-IgA and N-IgG were at least two times greater in BF fixation than in FS fixation. The 
highest relative contribution to the total variance due to the biological variations between 
the individuals were observed in the FS-fixed specimens. 
Regarding the most appropriate IH parameters, the percentages of IgA-, IgG-, 
and IgM-containing plasma cells, the FS-fixation/PAP-staining combination resulted in 
the most favourable properties for quantitative purposes. With regard to the %IgA and 
%IgG, more than 93% of the total variance was due to the differences between the 
patients. The absolute contributions of the inter-observer variations to the total variances 
in %IgA, %IgG, and %IgM were smallest for the FS/PAP combination and their relative 
contributions to the total variances were about 1% (Table 5). Moreover, the FS/PAP 
combination also resulted in the smallest absolute and relative contributions of the 
unknown residual random effects to the total variances in the percentages of Ig-containing 
plasma cells (Table 5). 
Discussion 
Masking of antigenic determinants due to fixation in buffered formol and formol 
saline solutions, resulting in a systematic underestimation in the numbers of Ig-containing 
plasma cells is a well known phenomenon which has been demonstrated by several 
investigators in semi-quantitative and quantitative studies [4,6-8]. No consensus of 
opinion exists regarding the degree of the inaccuracy due to this underestimation. Piris 
and Thomas [8] reported a statistically highly significant (P=0.001) difference in the 
number of immunohistologically detectable plasma cells in FS-fixed rectal mucosa as 
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TABLE 2 
Results of the nested analysis of variance for absolute numbers of IgA-, IgG- and IgM-containing 
plasma cells. 
Systematic effect 
Fixation 
Technique 
Random effect 
Fixation 
Technique 
Observer 
Component of variance 
í¡(lolal) 
ï2(patient) 
i2(fixat]on) 
t:(iechnique) 
ï2(observer) 
!2(residual) 
N-IgA 
П f I ƒ2) 
27 8(1,3) 
120(1,7) 
20 2 (4,8) 
0 9(8,30) 
12 0(2,30) 
i 2 
24 90 
8 11 
10 74 
0 
2 46 
3 59 
Ρ 
001 
0 01 
<000I 
0 50 
<000l 
rc(%) 
1000 
32 6 
43 1 
00 
99 
14 4 
N-IgG 
Hf\J2) 
0 9(1,3) 
2 6(1,7) 
3 4 (4,8) 
3 3 (8,30) 
16 3 (2,30) 
s' 
2 97 
1 34 
0 54 
031 
0 38 
040 
Ρ 
0 40 
0 15 
004 
0 008 
<000l 
г с (%) 
100 0 
45 1 
18 2 
104 
128 
135 
N-IgM 
F(/l/2) 
49(1,3) 
0 3(1,7) 
7 7 (4.8) 
0 6 (8.30) 
0 5 (2,30) 
Î 2 
0 040 
0015 
0010 
0 
0 
0015 
Ρ 
ou 
0 59 
0009 
0 77 
0 59 
г с (%) 
1000 
37 5 
25 0 
00 
00 
37 5 
N-IgA/IgG/IgM = number of IgA/IgG/IgM-containing plasma cells; F, value of F-statistics: ƒ = 
degrees of freedom; s1, estimated variance; r.c, relative contribution to total variance. 
TABLE 3 
Results of the nested analysis of variance for percentages of IgA-, IgG-
plasma cells. 
and IgM-containing 
Systematic effect 
Fixation 
Technique 
Random effect 
Fixation 
Technique 
Observer 
Component of variance 
i2(total) 
t2(palicnl) 
ï2(fixation) 
v2(lechnique) 
s2(observer) 
j:(residual) 
%IgA 
F(f\J2) 
06(1,3) 
0 8(1,7) 
3 9 (4,8) 
4 6 (8,30) 
8 1 (2,30) 
.
2 
33 54 
9 85 
10 97 
590 
2 18 
491 
Ρ 
0 49 
0 39 
0 05 
<0001 
0 002 
rc(%) 
1000 
28 6 
32 7 
176 
65 
14 6 
"/.IgG 
FU\f2) 
07(1.3) 
1 1 (1,7) 
3 7 (4,8) 
4 8 (8.30) 
13 6(2,30) 
J 2 
33 62 
10 65 
940 
561 
351 
4 45 
Ρ 
0 45 
0 32 
0 06 
<0001 
<000l 
rc(%) 
1000 
31 7 
28 0 
167 
104 
13 2 
%IgM 
П ƒ 1/2) 
0 002(1,3) 
16 (1,7) 
3 4 (4,8) 
0 5 (8.30) 
7 3 (2.30) 
s
1 
0 93 
0 34 
0 07 
0 
015 
0 37 
Ρ 
0 97 
0 25 
0 06 
0 85 
0 003 
гс(%) 
100 0 
36 6 
75 
00 
16 1 
39 8 
%-IgA/IgG/IgM = percentage of IgA/IgG/IgM-containing plasma cells; F, value of F-statistics: ƒ 
= degrees of freedom; s2, estimated variance; r.c, relative contribution to total variance. 
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TABLE 4 
Results of analysis of variance for the numbers of IgA-
each of the four fixative/technique combinations. 
IgG- and IgM-containing plasma cells for 
%-IgA 
BFPAP 
BFIIP 
FSPAP 
FS,1IP 
%-івС 
BFPAP 
BFIIP 
FSPAP 
FS'IIP 
%-IgM 
BFPAP 
BFIIP 
FSPAP 
FSIIP 
Mean 
83 32 
8101 
8153 
84 30 
14 50 
16 97 
13 10 
1366 
2 18 
201 
2 17 
204 
SD 
5 67 
464 
5 19 
766 
540 
5 01 
5 10 
7 58 
0 85 
0 96 
101 
090 
ν
1
 Total 
32 13 (100%) 
21 54(100%) 
26 94(100%) 
58 60 (100%) 
29 20(100%) 
25 15(100%) 
26 00(100%) 
57 40(100%) 
0 73(100%) 
0 93(100%) 
102(100%) 
0 81 (100%) 
s' Patient 
26 20(81 5%) 
10 11 (46 9%) 
25 79 (95 7%) 
48 77 (83 2%) 
22 47 (77 0%) 
13 02(518%) 
24 22 (93 2%) 
46 22 (80 5%) 
0 28(38 4%) 
0 29(312%) 
0 58 (56 9%) 
0 22(27 2%) 
s
1
 Observer 
2 54 (7 9%) 
2 31 (10 7%) 
0 26(10%) 
5 16 (8 8%) 
3 01 (10 3%) 
5 32 (21 2%) 
0 32(12%) 
8 04(14 0%) 
0 11 (15 1%) 
0 19 (20 4%) 
0 (0%) 
009(11 1%) 
s
2
 Residual 
3 39(10 60%) 
9 12 (42 30%) 
0 89 (3 30%) 
4 67 (8 00%) 
3 72(12 70%) 
6 81 (27 10%) 
1 46 (5 60%) 
3 14 (5 50%) 
0 34(46 60%) 
0 45 (48 40%) 
0 44 (43 10%) 
0 53(61 70%) 
Interobs var 
f{2 6) 
400 
201 
2 17 
5 42 
4 24 
4 13 
187 
11 22 
2 32 
2 65 
0 42 
174 
Ρ 
0 08 
021 
0 20 
0 05 
0 07 
0 07 
0 23 
0009 
0 18 
0 15 
0 68 
0 25 
Mean, mean number of Ig-containing plasma cells per 0.04 nun1 SSG tissue; N-IgA/IgG/IgM, 
number of IgA/IgG/IgM-containing plasma cells; SD, standard deviation; s1, estimated variance; 
Interobs. var., inter-observer variation; BF, buffered formol; PAP, peroxidase anti-peroxidase; 
FS, formol sublimate; IIP, indirect immunoperoxidase; F, value of F-statistics, degrees of 
freedom are given within parentheses. 
TABLE 5 
Results of analysis of variance for the percentages of IgA-, IgG- and IgM-containing plasma cells 
for each of the four fixative/technique combinations. 
N-IgA 
BFPAP 
BFIIP 
FS/PAP 
FS/IIP 
N-IgG 
BF,PAP 
BF/IIP 
FS'PAP 
FS/IIP 
N-lgM 
BF/PAP 
BF/IIP 
FS/PAP 
FS/IIP 
Mean 
9 45 
10 49 
13 82 
15 16 
181 
2 29 
241 
291 
0 247 
0 251 
0 351 
0 380 
SD 
3 53 
4 40 
5 08 
4 52 
1 16 
144 
1 54 
2 49 
s
2
 Total 
12 47(100%) 
19 37(100%) 
25 83 (100%) 
20 46(100%) 
1 34 (100%) 
2 08(100%) 
2 36(100%) 
6 22(100%) 
0 155 0 024(100%) 
0 152 0 023(100%) 
0 230 0 053(100%) 
0 226 0 051 (100%) 
j 2 Patient 
6 95 (55 7%) 
12 77(65 9%) 
18 91 (73 2%) 
15 21 (74 8%) 
0 75(56 0%) 
0 95(45 7%) 
2 13(90 3%) 
5 02 (80 7%) 
0 011 (46 1%) 
0 012(53 0%) 
0 033 (62 3%) 
0 022 (42 5%) 
s
2
 Observer 
2 97 (23 8%) 
4 13 (21 3%) 
1 44 (5 6%) 
0 32(16%) 
0 36 (26 9%) 
0 77 (37 0%) 
0 07 (3 0%) 
0 58 (9 3%) 
0 (0%) 
0 (0%) 
0 (0%) 
0 (0%) 
s
2
 Residual 
2 55 (20 45%) 
2 47(12 80%) 
5 48(21 20%) 
4 83 (23 60%) 
0 23(17 20%) 
0 36(17 30%) 
0 16(6 80%) 
0 62(10 00%) 
0 013(53 90%) 
0 011 (47 00%) 
0 020(37 70%) 
0 029 (57 50%) 
Interobs var 
П.2.6} 
5 66 
7 68 
2 05 
126 
7 14 
9 58 
2 69 
4 74 
0 33 
0 43 
0 03 
0 33 
I Ρ 
004 
0 02 
021 
0 35 
0 03 
001 
0 15 
0 06 
0 73 
0 67 
0 97 
0 67 
Mean, mean number of Ig-containing plasma cells per 0.04 mm2 SSG tissue; %-IgA/IgG/lgM, 
percentage of IgA/IgG/IgM-containing plasma cells; SD, standard deviation; s2, estimated 
variance; Interobs. var., inter-observer variation; BF, buffered formol; PAP, peroxidase anti-
peroxidase; FS, formol sublimate; IIP, indirect immunoperoxidase; F, value of F-statistics, 
degrees of freedom are given within parentheses. 
31 
compared to rectal mucosa fixed in formol saline. Hey worth [4], using the same fixatives 
however, found only a weakly significant difference (0.02 <P< 0.05). In the present 
study on heavy chains a statistically significant (P=0.01) systematic underestimation in 
the numbers of Ig-containing plasma cells due to fixation was only found for Ig A. 
Furthermore it was demonstrated that the IH procedure also introduced systematic errors. 
Although the same concentrations of primary antisera were used in both PAP and IIP 
staining procedures, and although the PAP technique is considered to be more sensitive, 
higher numbers of Ig-containing plasma cells were found in the IIP technique for both 
fixatives. This systematic staining effect was even statistically significant (P=0.01) for 
N-IgA. 
Moreover, our study disclosed that %IgA, %IgG, and %IgM were not 
systematically influenced by the choice of fixative or IH staining procedure. This implies 
that the relative numbers of Ig-containing plasma cells are much more appropriate for 
constructing accurate quantitative IH diagnostic criteria than the numbers of Ig-containing 
plasma cells. From a purely theoretical point of view this finding is not surprising, 
because these relative parameters are less sensitive for systematic errors. 
Another important result from the study of Piris and Thomas [8], which is not 
well emphasized in the literature, is that the difference between the numbers of Ig-
containing plasma cells measured after fixation in FS and formol-saline was not constant 
and varied considerably between the individuals. However, they did not explain this 
phenomenon, which is a striking example of a random fixation effect. The present study 
demonstrates that not only tissue fixation, but also IH staining, introduces considerable 
random effects on both the absolute and relative numbers of Ig-containing plasma cells. 
The relative contribution of the sum of the random effects due to fixation, IH staining, 
inter-observer variations and other effects of unknown origin to the total variance 
appeared to be even greater than the contribution of the biological variation between the 
individuals. For %IgA the relative contribution of the biological variations between the 
individuals was even less than 30%. This highly undesirable situation may have 
important consequences on the applicability of quantitative IH diagnostic criteria, 
especially when the differences in the composition of the plasma cell infiltrates between 
the different pathologic entities are relatively small, as shown in Figure 3. 
The superiority of FS fixation to buffered formol and formol-saline solutions has 
been described by several investigators and is based on different arguments [3,4,6-8]. 
Bosman et al. [3] used qualitative criteria, such as the preservation of tissue morphology, 
the intensity of immunostaining of plasma cells, the localization of immunostaining, and 
the lack of a nonspecific background staining to demonstrate the superiority of FS 
fixation when compared with a variety of other fixatives. Curran and Gregory [4], 
comparing a variety of fixatives and using qualitative (preservation of histological 
structure) and semi-quantitative criteria, also indicated FS as an excellent fixative for 
demonstration of cytoplasmatic Ig. Other investigators mentioned the higher numbers of 
Ig-containing plasma cells, resulting in more accurate measurements as a favourable 
property of FS fixation [6,8]. The superiority of FS fixation to BF fixation for 
quantitative IH analysis of plasma cell infiltrates finds further support in the present 
study. The reproducibility of the numbers of Ig-containing plasma cells by different 
observers was obviously better in FS- fixed tissue specimens, because it did not result in 
statistically significant inter-observer variations. Indeed, other fixatives may reveal 
qualitatively satisfactory results in the IH demonstration of Ig-containing plasma cells [4]. 
However, before any other fixative is used in the IH demonstration of Ig-containing 
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plasma cells for quantitative puiposes, accuracy and precision of the result, given the 
fixative, must be warrented. 
>-
σ 
О Ю 20 30 40 50 
%lgG-CONTAINING PLASMA CELLS 
Fig. 3. In the upper part of the figure the Gaussian distribution functions of the percentages of 
IgG-containing plasma cells for two populations of patients with invented diseases Α (μ
Α
=20, 
(7^=4) and Β (μ
Β
=30, σ21,=4) are given. The mean values and variances are given within 
parentheses. In this idealized situation there is a small overlap of the two populations and using 
the 25% IgG threshold value to allocate patients in group A or В results in 1.2% 
misclassifications. An accurate immunohistological technique, with a limited precision due to 
random effects, was used to determine the percentages of IgG-containing plasma cells and the two 
distribution functions are given in the lower part of the figure. The sample means are equal to the 
population means due to the high accuracy of the chosen immunohistological method. However, 
the Gaussian curves have larger variances (cr1A=cr5,= 12) with a relative contribution of the 
random effects to the variance of 66.7%, resulting in a considerable overlap of the two Gaussian 
curves. Application of the 25% IgG threshold value to allocate patients in group A or В gives 
rise to 15% misclassifications. In such situations the reliability of the diagnostic criterion will be 
improved by reduction of the random effects for instance by the use of more standardized 
techniques. The necessity of eliminating random effects decreases with an increasing distance 
between the population means. 
The application of protease digestion after buffered formol or formol-saline 
fixation to unmask immunoreactive sites and enhance the accuracy of IH staining 
procedures, as proposed by several investigators [4,6,7], is far from attractive and is not 
advocated for quantitative purposes. Although not explicitly investigated in this, or other 
studies, it is obvious that protease digestion is an important source of random errors, 
since the amount of masking is strongly correlated to the duration of fixation [7] and the 
unmasking effect of protease is dependent on the temperature and duration of the 
digestion procedure, which must be determined empirically [9]. 
We conclude that the applicability of IH diagnoses is not only determined by the 
specificity of the antisera but also by the tissue fixation and IH staining procedures, 
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especially in quantitative pathology. Percentages of Ig-containing plasma cells obtained 
from the numbers of Ig-containing plasma cells measured in FS-fixed and PAP-stained 
tissue sections are most appropriate for the construction of accurate, precise, and 
reproducible quantitative IH diagnostic criteria. 
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Abstract 
Objective. The aim of the present study was to evaluate the diagnostic value of 
quantitative inununohistologic criteria for Sjogren's syndrome (SS) in labial salivary 
gland biopsies. 
Methods. Quantitative inununohistologic examination was performed on the 
labial salivary gland biopsies of 80 healthy controls, 32 patients with primary SS, 14 
patients with secondary SS, 5 with "probable" SS, 36 with keratoconjunctivitis sicca 
(KCS) with a lymphocytic focus score <1 on the lipbiopsy, and 18 with rheumatoid 
arthritis (RA) without clinical evidence of SS. 
Results. This is the first study to show that inununohistologic criteria for SS, 
based on the percentages IgA- and IgG-containing plasma cells are able to 1) 
confirm the diagnosis SS in labial salivary glands of KCS patients in the absence of 
a grade IV lymphocytic adenitis; and 2) distinguish between a grade IV focal 
lymphocytic adenitis in the labial salivary glands of SS patients and RA patients 
without SS. 
Conclusion. Quantitative inununohistologic criteria were shown to be much more 
sensitive and disease specific than the widely accepted grade IV lymphocytic adenitis, 
which corresponds with a lymphocytic focus score > 1 , and these criteria should be 
included in the international diagnostic criteria for SS. 
Introduction 
Sjogren's syndrome (SS) is a chronic autoimmune exocrinopathy, that affects lacrimal 
and salivary glands [1,2]. Polyclonal B-cell activation, characterized by 
hypergammaglobulinemia and autoantibody formation is a common feature of SS [1-5]. 
Diagnosis of SS requires confirmation of salivary gland involvement [6-8]. The widely 
accepted lymphocytic focus score criterion, however, has a low diagnostic yield [6-8]. 
This criterion deems positive a labial salivary gland (LSG) specimen having > 1 
lymphocytic focus (aggregate of ^ 50 lymphocytes and histiocytes) per 4-mm2 LSG 
tissue, which corresponds to grade IV lymphocytic adenitis on the Chisholm and Mason 
scale (9), and it is considered the most disease-specific criterion for SS [6-8]. In up to 
74% of SS patients described in the literature, a lymphocytic focus score > 1 in the LSG 
biopsy was not found [9-15]. In contrast, grade IV focal lymphocytic adenitis of LSGs 
indistinguishable from that of SS has been seen in 5%-10% of normal individuals [16,17], 
in 18% of patients with connective tissue diseases [18], in 36% of patients with 
myasthenia gravis [19], as well as patients with primary biliary cirrhosis [20], graft 
versus host disease [21], and acquired immunodeficiency syndrome [22,23]. 
As early as 1972, Anderson et al [11] showed that LSGs from SS patients are a site of 
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TABLE 1 
Subjects whose labial salivary gland tissues were evaluated, grouped according to diagnosis. 
No of 
Group, mean age (range) subjects Diagnosis* 
Group [, 37 7 years (0-78 years) 80 Heallhy controls ("learning set' ) intraoral surgery for cosmetic or 
preprosthetic purposes, no evidence of systemic disease 
Group [I, 50 7 years (14-76 years) 40 Sjogren's syndrome ("learning set ') keratoconjunctivitis sicca (by 
slit lamp examination, plus at least 2 of the following test results 
positive Schirmer's test <5 mm wetting in 5 minutes, van 
Bijsterveld s score >3, tear break-up time <10 seconds, or 
decreased tear lysozyme or laclofemn concentration), focal 
lymphocytic adenitis of labial salivary glands, with a lymphocytic 
focus score > I. and serologic abnormalities 
Group 111. 49 3 years (26-73 years) 11 Sjogren's syndrome ("test set' ) 6 patients with Sjogren's syndrome 
as defined for group 11. and 5 patients with probable Sjogren's 
syndrome (sicca symptoms in the eyes and/or Schirmer's test <5 
mm of welting in 5 minutes and subjective report of oral dryness, 
and focal lymphocytic adenitis of labial salivary glands, with a 
lymphocytic focus score >1. and serologic abnormalities) 
Group IV, 47 6 years (16-78 years) 36 Keratoconjunctivitis sicca (as denned for group II) and a lymphocytic 
focus score <1 on labial salivary gland biopsy, no previously 
diagnosed connective tissue disease 
Group V, 58 6 years (42-78 years) 18 Rheumatoid arthntis volunteers without subjective symptoms of 
ocular or oral dryness or salivary gland swelling and clinically not 
suspected of having Sjogren s syndrome 
* Serologic abnormalities consisted of elevation of serum IgA IgG. or IgM levels and/or presence of autoantibodies (rheumatoid factor and/or 
antmuclear antibody and/or anti-SS-A and/or anli-SS-B) bvaluation of eye involvement in patients with probable Sjogren's syndrome was not 
complete, only the Schirmer's test was performed 
autoantibody formation, a finding which has been confirmed by Fox et al [24]. In 
addition, increased proportions of IgG- and IgM-containing plasma cells in LSG tissue 
from SS patients have been reported [10,25]. Recently, two quantitative immunohistologic 
diagnostic criteria for SS utilizing these altered proportions of immunoglobulin-containing 
plasma cells in the LSG tissue of SS patients have been described [26,27]. One criterion 
[26] was based on the percentages of IgA- and IgG-containing plasma cells in the LSG 
tissue. These percentages are used in a discriminant function ([OF] = 0.062 χ %IgA -
0.088 χ %IgG - 4.387), by which a diagnosis of SS can be made if the DF-score is lower 
than -1.19. Speight et al [27] based their criterion on increased percentages of IgM-
containing plasma cells in the LSG tissue. With their criterion, SS can be diagnosed if the 
percentage of IgM-containing plasma cells in the LSG tissue is > 1 0 . Although both 
studies consisted of only small groups of patients, both criteria were found to be highly 
specific and sensitive. LSG biopsies from patients with related diseases, such as 
rheumatoid arthritis (RA) without SS, and from patients with keratoconjunctivitis sicca 
(KCS) with a lymphocytic focus score < 1 have not been evaluated. 
We conducted the present study to evaluate the diagnostic value of the two quantitative 
immunohistologic criteria in a group of 46 patients with SS (32 with primary SS and 14 
with secondary SS), S patients with "probable SS", 36 patients with KCS and a 
lymphocytic focus score < 1 on LSG biopsy, 18 patients with RA clinically not suspected 
to have SS, and 80 healthy control subjects. We also evaluated the interobserver 
reproducibility of the quantitative immunohistologic diagnoses. 
Patients and methods 
Subjects. We used LSG biopsies from 185 subjects grouped as indicated in Table 1. 
After informed consent was obtained, biopsies were performed according to the horizontal 
incision technique described by Greenspan et al [28]. The diagnosis of SS had been based 
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on the criteria described by Daniels and Talal [29]. All patients with RA met at least 4 of 
the 7 specific criteria described by the American College of Rheumatology (formerly, the 
American Rheumatism Association) [30]. 
Tissue processing and measurements. The LSG biopsies were fixed in a formol 
sublimate solution and embedded in paraffin. Lymphocytic focus scoring [9] was 
performed on heamatoxylin and eosin-stained sections. Serial sections (5 μΐη) were used 
for immunohistologic staining. The mercury pigment was removed from the sections by 
immersion in Lugol's iodine. Intracellular immunoglobulins of classes IgA, IgG, and IgM 
were demonstrated by Stemberger's unlabeled peroxidase-antiperoxidase (PAP) procedure 
[31,32]. Antisera were used at the following dilutions: monospecific primary antisera 
raised in rabbits against IgA and IgM, 1:800; IgG, 1:200; swine anti-rabbit serum, 1:20; 
and rabbit PAP complex, 1:800. Monospecificity of the antisera against the heavy chains 
was obtained by removing light chain reactivity by absorption with Bence Jones light 
chains. 
All antisera were diluted in phosphate buffered saline (PBS), and the sections were 
incubated with the primary antisera for 1 hour, with swine anti-rabbit serum for 30 
minutes, and with rabbit PAP complex for 20 minutes. All incubations were performed at 
room temperature. Optimal dilutions were found by chess board titration. Control studies 
were performed by substituting PBS for the primary antisera. Prior to incubation with the 
primary antisera, the endogeneous peroxidase activity was inhibited by incubation for 30 
minutes with a solution of methanol containing 1% hydrogen peroxide; nonspecific 
background staining was blocked by incubation for 20 minutes with normal swine serum. 
All antisera were obtained from Dakopatts (Copenhagen, Denmark). The specificity of 
the antisera was confirmed by both Immunoelectrophoresis and double immunodiffusion. 
In double immunodiffusion, no reaction with purified kappa and lambda light chains was 
observed. The monospecificity for the various heavy chains of primary antisera was also 
tested both with an enzyme-linked immunosorbent assay, using human IgA, IgG, and IgM 
as antigens, and on monoclonal plasma cells in bone marrow biopsy specimens from 
selected myeloma patients. 
Percentages of IgA-, IgG-, and IgM-containing plasma cells (%IgA, %IgG, and 
%IgM) in the 5 ¿tm serial sections were determined as previously described [26], using a 
semiautomatic image analysis system (MOP Videoplan; Kontron, Munich, FRG). DF-
scores were determined by substitution of %IgA and %IgG in the discriminant function 
described in the Introduction. 
Laboratory tests. Serum immunoglobulin levels were determined by radial 
immunodiffusion or nephelometry. Rheumatoid factor was measured by the Rose-Waaler 
test. Antinuclear antibodies (ANA) were tested by indirect immunofluorescence on mouse 
liver sections, and antibodies to SS-A/Ro and SS-B/La by counterimmunoelectrophoresis 
and Western blotting. Clinical, serologic, histologic, and immunohistologic findings in the 
5 groups of subjects are presented in Tables 2 and 3. 
Statistics. A foreward stepwise linear logistic regression analysis was applied to 
%IgA, %IgG, %IgM, and DF-scores obtained from a "learning set" consisting of 80 
control subjects (group I) and 40 SS patients (group II), in order to select the best 
quantitative immunohistologic parameters for discriminating between healthy controls and 
SS patients. The results of the logistic regression were used to obtain the corrected 
probability (P„„) for unequal sample size. Ρ„„ is the probability of having SS, given the 
value (X) of a quantitative immunohistologic parameter, assuming equal prior 
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TABLE 2 
Clinical features, histologic and immunohistologic findings in labial salivary gland biopsy tissues, 
and laboratory values in patients with SS and probable SS*. 
Patient no 
(other 
diagnosis) 
81 
82 
83 (MCTD) 
84 
85 
86 (SSc) 
87 
88 
89 
90 
91 (RA) 
92 
93 (PBC) 
94 
95 
% 
97 
98 
99 
100 (RA) 
101 (RA) 
102 
103 (RA) 
104 
105 (MCTD) 
106 
107 
108 
109 
MO 
111 
112 
ИЗ 
114 
115 (SSc) 
116 
117 
118 (COLE) 
119 
120 
121 
122 
123 
124 
125 
126 
127 (MCTD) 
128 (RA) 
129 
130 (SSc) 
131 (RA) 
Group 
II 
И 
li 
И 
II 
II 
II 
II 
II 
II 
11 
II 
II 
II 
II 
II 
II 
II 
II 
11 
II 
II 
II 
II 
II 
11 
II 
II 
II 
lì 
II 
l i 
li 
li 
li 
li 
li 
II 
II 
II 
III 
III 
III 
III 
HI 
III 
III 
HI 
HI 
HI 
HI 
KCS 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
NCb 
NCF 
NCF 
NCF 
NCE 
+ 
+ 
+ 
+ 
+ 
+ 
xs 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
-t-
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
SGS 
-
-
-
-
-
-
» 
-
+ 
+ 
-
-
-
-
+ 
+ 
-
+ 
-
-
-
-
-
+ 
+ 
-
-
-t-
-t-
-
-
+ 
-
+ 
-
-
-
-
+ 
+ 
-
+ 
-
+ 
-
-
-
-
-
-
-
Salivary gland 
LFS 
3 0 
2 6 
3 7 
2 6 
8 4 
7 9 
5 1 
3 7 
2 4 
2 5 
2 9 
2 9 
6 9 
6 3 
2 2 
4 0 
3 4 
7 4 
14 
3 5 
1 8 
5 3 
4 5 
2 4 
2 9 
2 1 
2 9 
2 9 
2 1 
3 0 
2 7 
4 4 
2 1 
3 7 
2 1 
10 6 
6 0 
4 7 
3 8 
4 0 
2 1 
3 1 
1 5 
4 9 
3 0 
3 6 
1 4 
2 0 
4 1 
3 2 
1 5 
DF 
score 
- 3 46 
- 4 07 
- 3 47 
- 4 62 
- 4 65 
- 3 74 
- 9 63 
- 5 36 
- 2 30 
- 6 64 
- 5 79 
- 5 88 
- 6 52 
- 3 24 
- 4 59 
- 5 99 
- 6 14 
- 6 99 
- 4 71 
- 3 84 
- 3 30 
- 5 17 
- 4 46 
- 4 75 
- 4 81 
- 5 27 
- 5 45 
- M 7 
- 2 34 
- 3 45 
- 5 22 
- 6 50 
- 3 55 
- 5 17 
- 3 51 
- 3 00 
- 3 74 
- 4 56 
- 6 47 
- 7 06 
- 2 51 
- 2 21 
- 4 40 
- 6 21 
- 6 48 
- 4 34 
- 2 80 
- 4 09 
- 7 53 
- 0 97 
- 3 46 
s 
%lgA 
56 4 
5 1 0 
4 4 3 
37 7 
7 0 
164 
19 0 
4 4 7 
67 3 
37 2 
30 6 
40 7 
190 
65 9 
47 5 
39 3 
43 9 
3 8 
48 8 
48 0 
47 0 
21 9 
52 3 
51 5 
40 7 
43 1 
28 5 
75 8 
69 1 
36 1 
49 6 
27 0 
62 3 
50 2 
60 1 
63 6 
18 4 
32 3 
29 2 
24 7 
66 5 
65 2 
34 0 
43 9 
36 3 
17 8 
59 7 
50 3 
28 8 
6 6 9 
59 8 
%lgM 
14 4 
16 6 
34 9 
33 1 
85 0 
79 4 
8 1 
12 9 
8 9 
10 9 
32 0 
137 
43 3 
0 8 
16 7 
14 8 
5 3 
64 1 
13 2 
24 4 
32 2 
53 9 
10 1 
8 1 
25 8 
16 6 
39 4 
4 0 
5 5 
49 0 
6 0 
30 0 
3 3 
5 5 
7 6 
7 3 
75 9 
43 1 
26 6 
27 6 
8 0 
13 6 
4 1 9 
4 4 
14 4 
70 2 
16 4 
17 7 
15 2 
24 9 
8 7 
bSR 
(mm/hour) 
138 
55 
70 
79 
84 
8 
32 
60 
10 
105 
87 
25 
28 
13 
70 
15 
78 
19 
18 
59 
28 
20 
13 
80 
5 
12 
10 
15 
54 
24 
44 
30 
41 
78 
19 
19 
9 
9 
65 
48 
7 
36 
48 
49 
103 
3 
7 
20 
75 
II 
62 
laboratory values 
IgG/IgM/IgA 
(gm/hter) 
34 1/5 2/3 4 
22 6/1 7/4 5 
11 3/3 0/2 6 
12 5/4 7/1 7 
7 0/4 0/1 5 
5 6/3 7/1 0 
19 7/2 7/1 3 
33 6/2 4/6 1 
16 9/1 6/1 2 
24 1/0 7/1 3 
15 6/1 1/2 3 
16 3/1 8/2 1 
7 7/7 5/2 7 
25 0/2 5/3 5 
38 8/4 3/3 6 
22 0/2 0/1 1 
40 6/1 2/4 3 
21 8/1 7/3 1 
21 4/1 0/4 4 
8 9/1 2/3 4 
ND/ND/ND 
9 4/3 6/1 4 
15 0/1 0/2 8 
16 6/0 3/5 1 
Il l/l 6/2 4 
23 3/3 5'2 5 
13 2/3 0/3 6 
16 2/1 0/1 7 
23 3/1 2/4 9 
8 8/3 2/2 1 
22 2/1 2/5 5 
17 3'2 8Ό 6 
25 9/4 5/6 0 
13 7/0 6/2 7 
7 8/0 8/1 4 
9 8/0 5/4 2 
12 4/1 2/3 0 
17 7/2 3/1 7 
27 1/2 1/1 0 
15 3'2 9/3 7 
19 4/0 8/4 1 
13 7/2 5/3 1 
19 7/3 4/1 8 
42 2/2 3/7 4 
36 6/3 6/5 4 
8 1/0 4/0 8 
15 4/1 1/4 5 
11 0/1 1/3 5 
40 7/1 5/5 0 
8 2/1 0/2 0 
12 2/1 3/1 6 
ANA 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
-
+ 
+ 
+ 
+ 
-
-
-
+ 
+ 
+ 
-
-
-
-
-
+ 
+ 
+ 
+ 
+ 
-
+ 
-
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
SS-A 
-
-
-
+ 
-
-
-
+ 
+ 
-
-
+ 
N D 
-
-
-
-
+ 
-
-
ND 
-
-
-
-
ND 
+ 
-
-
-
+ 
-
+ 
+ 
-
-
-
-
-
+ 
+ 
-
-
+ 
+ 
+ 
-
ND 
+ 
-
N D 
ss-В 
+ 
+ 
-
+ 
+ 
-
-
+ 
+ 
-
-
+ 
N D 
-
+ 
+ 
+ 
+ 
+ 
-
N D 
-
-
-
-
N D 
-
-
-
-
+ 
-t-
-
^ 
-
-
-
-
-
-
+ 
-
+ 
+ 
+ 
+ 
-
N D 
+ 
-
N D 
RF 
+ 
+ 
+ 
+ 
-
-
-
+ 
+ 
+ 
+ 
-
N D 
-
+ 
+ 
+ 
N D 
+ 
+ 
+ 
-
-
-
+ 
-
+ 
-
+ 
-
+ 
+ 
+ 
+ 
-
-
+ 
N D 
+ 
ND 
+ 
-
+ 
+ 
-
-
-
+ 
+ 
+ 
+ 
* Patients are groups II and HI Sjogren s syndrome (SS) patients as deñned in Table I KCS = keratoconjunctivitis sicca, XS = xerostomia 
(subjective) SGS - salivary gland swelling LFS = lymphocytic focus score DF score = discriminant function score (0 062 x %lgA - 0 088 
x %IgG - 4 387), ÇïlgA (IgM) = percentage of IgA (IgM)-conlaining plasma cells. bSR - erythrocyte sedimentation rale (normal <20), 
normal serum immunoglobulin values are IgG 4 7-13 3, IgM 0 4-2 4 IgA 0 3-2 5, AN A - antinuclear antibodies RF = rheumatoid factor, 
MCTD = mixed connective tissue disease SSc = systemic sclerosis RA - rheumatoid arthnlis PBC = primary biliary cirrhosis, ND = not 
done. CDLE = chronic discoid lupus erythematosus NCE = not completely evaluated 
39 
probabilities for controls and SS patients, and is given by: 
1 
P ^ (SS | X) = 
1 + EXP (b0 + b.X) 
The regression coefficients b0 and b, in the exponential function (EXP) can be estimated 
with a logistic regression analysis. A subject is classified as having SS if the probability 
is >0.5, and as not having SS if the probability is <0.5. The diagnostic threshold values 
of these quantitative immunohistologic parameters and their standard errors were also 
obtained from the linear logistic regression analysis, by the solution of Ρ„„ (SS | X) = 
0.5, which results in the best compromise between specificity and sensitivity. An 
overview of logistic regression analysis has recently been given by Bloch et al [33]. 
The quantitative immunohistologic data of the learning set (groups I and II) were used 
to construct, as well as to evaluate the performance of selection criteria. This procedure 
may give classification results that are too optimistically biased. To avoid this, a jackknife 
procedure was used in the logistic regression analysis. A test set of patients (group III) 
not included in logistic regression analysis was used for further validation of the 
classification results: 6 patients with SS and 5 patients with probable SS. 
Differences between groups were tested with the Mann Whitney U-test, and Chi-square 
test was used to analyze the discrete data for contingency tables. 
Reproducibility. Biopsy sections from group I and group II "cases" misclassified with 
our quantitative immunohistologic criteria, plus enough sections from randomly chosen 
cases to have a total of 20 healthy controls and 20 SS patients, were examined by 3 
independent observers, 1 physician (CB) and 2 technicians. The reliability of the 
quantitative immunohistologic parameters is determined by a systematic observer effect 
and a measurement error. The latter is caused by the fact that different observers do not 
select the same test fields for determination of the numbers of immunoglobulin containing 
plasma cells. Statistical significance of the systematic observer effects was studied with a 
two-way analysis of variance. The reliability of the quantitative immunohistologic 
parameters can be estimated with the results of the analysis of variance by incorporating 
the systematic observer effect in the measurement error [34]. 
Results 
Diagnostic criteria. The foreward stepwise linear logistic regression analysis revealed 
that the bivariate DF-score was the best parameter for discrimination between healthy 
controls (group I) and SS patients (group II). The diagnostic threshold value of DF-score 
and its standard error are -2.0 and 0.2, respectively. With this bivariate quantitative 
immunohistologic criterion, a diagnosis SS can be made if the DF-score is less than -2 
(Figure 1A). The probability that a given subject has SS, given the DF-score, is 
represented graphically in Figure 2A. 
A foreward stepwise linear logistic regression analysis applied only to univariate 
immunohistologic parameters (%IgA, %IgG, and %IgM) revealed that %IgA was the best 
discriminator between groups I and II. The diagnostic threshold value of %IgA and its 
standard error are 70 and 2, respectively. With this univariate criterion the diagnosis of 
SS can be made if %IgA is <70 (Figure IB). The probability of a subject having SS, 
given the %IgA value, is represented graphically in Figure 2B. 
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TABLE 3 
Clinical features, histologic and inununohistologic findings in labial salivary gland biopsy tissues, 
and laboratory values in patients of groups IV and V. 
Patient 
no 
(group) 
132 (IV) 
133 (IV) 
134 (IV) 
135 (IV) 
136 (IV) 
137 (IV) 
138 (IV) 
139 (IV) 
140 (IV) 
141 (IV) 
142 (IV) 
143 (IV) 
144 (IV) 
145 (IV) 
146 (IV) 
147 (IV) 
148 (IV) 
149 (IV) 
150 (IV) 
151 (IV) 
152 (IV) 
153 (IV) 
154 (IV) 
155 (IV) 
156 (IV) 
157 (IV) 
158 (IV) 
159 (IV) 
160 (IV) 
161 (IV) 
162 (IV) 
163 (IV) 
164 (IV) 
165 (IV) 
166 (IV) 
167 (IV) 
168 (V) 
169 (V) 
170 (V) 
171 (V) 
172 (V) 
173 (V) 
174 (V) 
175 (V) 
176 (V) 
177 (V) 
178 (V) 
179 (V) 
180 (V) 
181 (V) 
182 (V) 
183 (V) 
184 (V) 
185 (V) 
KCS 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
-
-
-
+ 
+ 
-
-
-
-
-
-
-
-
-
-
xs 
+ 
+ 
+ 
-
+ 
+ 
-
-
-
+ 
-
-
-
+ 
-
-
+ 
+ 
-
-
-
-
+ 
-
-
+ 
-
-
+ 
-4-
-
+ 
+ 
+ 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
SGS 
_ 
+ 
-
+ 
-
-
-
+ 
+ 
-
+ 
-
-
-
-
-
-
+ 
-
-
-
+ 
+ 
-
-
-
-
-
-
-
-
-
+ 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Salivary glands 
LFS 
0 3 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
07 
0 
0 6 
0 
0 6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 9 
0 
0 
32 
1 4 
07 
18 
0 4 
06 
1 2 
0 
05 
10 
1 3 
05 
03 
05 
1 7 
23 
2 1 
0 
DF 
score 
009 
-1 23 
088 
0 37 
0 93 
-2 27 
0 38 
048 
0 32 
-0 93 
1 53 
0 97 
-0 58 
-1 01 
0 42 
-4 41 
-1 20 
-2 55 
-0 05 
-0 01 
-0 15 
-0 16 
-0 02 
0 59 
-0 76 
0 98 
-3 22 
0 27 
0 22 
0 50 
0 71 
1 40 
- 2 63 
-4 II 
009 
0 38 
-1 29 
1 30 
0 93 
-1 18 
1 15 
-0 05 
-107 
-0 63 
140 
-0 96 
1 II 
1 28 
1 32 
-0 34 
031 
-0 10 
0 14 
1 09 
%IgA 
85 6 
74 8 
91 6 
87 4 
93 4 
67 9 
88 7 
89 2 
87 5 
79 7 
98 1 
93 2 
81 5 
69 5 
88 9 
55 5 
77 8 
680 
84 7 
86 2 
86 0 
85 1 
86 4 
908 
814 
94 0 
65 6 
88 4 
88 1 
902 
90 1 
969 
666 
47 7 
88 4 
87 0 
72 8 
95 7 
93 0 
74 9 
943 
85 9 
75 0 
810 
97 1 
660 
93 8 
95 7 
95 3 
84 7 
87 9 
82 8 
86 4 
940 
VclgM 
50 
84 
36 
52 
1 2 
82 
3 1 
32 
43 
36 
00 
20 
44 
19 9 
32 
5 1 
36 
49 
50 
28 
1 6 
30 
24 
18 
25 
07 
1 4 
22 
23 
1 9 
43 
05 
64 
219 
0 3 
6 0 
II 2 
1 5 
20 
88 
22 
29 
9 9 
4 6 
02 
26 4 
26 
12 
25 
1 6 
43 
76 
4 1 
20 
ESR 
(mm/hour) 
6 
15 
38 
29 
10 
15 
6 
38 
2 
10 
1 
6 
10 
30 
1 
17 
7 
17 
6 
3 
15 
10 
12 
4 
7 
3 
5 
6 
14 
2 
6 
12 
14 
42 
8 
8 
24 
27 
9 
8 
35 
19 
36 
85 
10 
82 
9 
17 
44 
14 
% 
25 
28 
50 
Laboratory values 
IgG/IgM/lgA 
(gm/liter) 
9 6/1 7/0 9 
15 9/1 7/1 7 
9 2/14/2 1 
16 8/2 212 1 
ND/ND/ND 
17 2/3 7/2 0 
9 8/2 3/1 8 
ND/ND/ND 
9 1/1 8/1 7 
12 0/2 2/2 5 
11 7/2 3/2 5 
8 1/0 7/2 6 
12 2/1 5/2 0 
15 2/6 6/1 8 
7 3/1 9/1 1 
18 8/0 7/1 7 
9 6/1 9/2 0 
14 7/1 2/2 1 
7 3/2 6/1 1 
12 5/1 8/1 6 
9 4/0 4/1 9 
12 (VI 4/0 6 
12 1/0 7/2 1 
11 0/2 2/2 9 
13 3/1 6/3 5 
9 6/4 9/2 4 
15 3/1 0/2 8 
Il 8/1 0/1 0 
10 6/1 3/1 8 
12 0/1 3/2 3 
9 2/1 7/3 7 
6 4/1 7/1 2 
21 9/2 1/3 1 
19 7/2 3/6 4 
16 3/1 1/4 6 
14 5/3 9/1 8 
116/12/2 9 
13 1/1 4/7 4 
9 6/0 8/2 4 
8 8/0 6/1 4 
8 6/1 3/2 7 
1С β/1 0/3 I 
17 l/l 3/3 8 
15 5/1 2/2 5 
12 7/0 6/3 4 
12 9/1 4/2 2 
10 9/1 7/3 1 
7 0/0 4/0 9 
11 9/2 2/2 9 
7 0/0 5/1 7 
15 0/2 4/4 8 
11 3/1 8/1 5 
15 0/0 8/2 3 
ND/ND/ND 
ANA 
_ 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
ND 
-
-
-
-
-
-
-
-
-
-
+ 
+ 
-
-
+ 
+ 
+ 
+ 
+ 
-
+ 
-
+ 
+ 
-
+ 
-
+ 
+ 
+ 
-
+ 
SS A 
_ 
-
-
-
-
-
-
-
-
-
-
-
-
— 
-
-
-
-
-
-
-
ND 
-
-
-
-
-
_ 
-
-
-
-
-
-
-
-
-
-
-
-
-
_ 
-
-
-
-
ND 
-
ND 
-
-
ND 
-
ND 
SS-B 
_ 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
ND 
-
-
-
-
-
-
-
-
-
-
+ 
+ 
-
-
-
-
-
-
-
_ 
-
-
-
-
ND 
-
ND 
-
-
ND 
-
ND 
RF 
_ 
-
-
-
-
-
-
-
-
-
-
-
-
— 
-
-
-
-
-
ND 
-
-
— 
-
+ 
-
-
-
-
-
— 
-
+ 
+ 
-
-
+ 
+ 
+ 
-
+ 
-
+ 
+ 
-
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
* See Table 2 for definitions and normal values and Table I for descnption of groups 
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Fig. 1. A, Discriminant function (DF) scores of all study subjects. The best separation of healthy 
controls (group I) and Sjogren's syndrome patients (group II) is obtained at a diagnostic threshold 
of -2 (dotted line). Broken line represents a DF-score of -1.19. B, Percentage of IgA-containing 
plasma cells (%IgA) of all study subjects Dotted line represents diagnostic threshold of 70%. See 
Table 1 for description of groups. 
Fig. 2. A, Probability of having Sjogren's syndrome (SS), given the DF-score. The graph is very 
steep at the cut off point of -2, which indicates that the diagnosis of SS rapidly becomes probably 
if the DF-score is below -2. The plot is obtained from the formula: 
1 
P „ (SS | DF-score) = 
1 + EXP (7.54 + 3.663 χ DF-score) 
where ?„ = corrected Ρ value and EXP = exponential function. B, Probability of having SS, 
given 9bIgA. The graph is also very steep at the diagnostic threshold value of %IgA = 70. The 
plot is obtained from the formula: 
1 
POT (SS I %IgA) = 
1 + EXP (-33.143 + 0.474 χ %IgA) 
See Figure 1 for other definitions and Table 1 for definition of groups. 
Fig. 3. Probability of a diagnosis Sjogren's syndrome (SS) calculated for each subject of this 
study, given A, the DF-score and B, the %IgA (formulas given in Figures 2A and В 
respectively). Dotted line represents the critical value at a probability of O.S which is used to 
classify subjects as having or not having SS. Note that the probabilities calculated from the DF-
scores (A) are farther from the O.S line than are those calculated from the %IgA (B). See Figure 
1 for other definitions and Table 1 for description of groups. 
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Classification results of the group I and II subjects. Application of the "DF-score 
less than -1.19" criterion, proposed in a previous study [26], to the 120 subjects of 
groups I and II resulted in misclassification of 4 subjects in group I, whereas none of the 
group II patients was misclassified (Figure 1A). These classification results correspond to 
a specificity of 93.7% and sensitivity of 100%. The "DF-score less than -2" criterion, 
obtained from the logistic regression analysis, gave 1 misclassification in group I and 1 in 
group II (Figure 1A). The latter classification results correspond to a specificity of 98.8% 
and sensitivity of 97.5%. In Figure 1A, the 2 diagnostic threshold values for DF-score 
are represented by different broken lines. 
Application of the univariate diagnostic criterion "%IgA < 7 0 " resulted in 1 
misclassification in group I and 1 in group II (Figure IB). However, the jackknife 
procedure revealed that these classification results of the "%IgA < 7 0 " criterion were 
favourably biased; therefore, the jackknifed classification results for "%IgA < 7 0 ", with 
a specificity of 98.8% and sensitivity of 95.0%, are more realistic. 
Figures ЗА and В show the probabilities of having SS for each subject of groups I and 
II. The probabilities of 0.5, which are used to classify subjects as SS or non-SS, are 
represented by the dotted lines. Given the DF-score, the probabilities of having SS are 
farther from the threshold (0.5) than the probabilities obtained from %IgA (compare 
Figure ЗА with 3B). 
II III IV ν 
patients дгоцэ nimber 
II III IV 
patients grtxp пилЬ г 
В 
Fig. 4. A, Percentage of IgM containing plasma cells (%IgM) of all study subjects Note the large 
overlap between healthy controls (group I) and Sjogren's syndrome patients (group II). Dotted line 
represents diagnostic threshold of 10. B, Lymphocytic focus scores of all subjects of this study. 
Groups II, HI, and IV were selected for study based on lymphocytic focus score (see Patients and 
Methods). Dotted line represents diagnostic threshold of lymphocytic focus score of 1; broken line 
represents the recently proposed diagnostic threshold of 2 (see ref. 8). See Table 1 for definitions 
of groups. 
Figure 4A shows classification of groups I and II subjects according to the 
"%IgM >10" criterion proposed by Speight et al [27]. Clearly, this criterion results in 
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great overlap between SS patients and healthy controls. The specificity of this criterion is 
93.7% and the sensitivity is 70.0%. 
In Figure 4B, the lymphocytic focus scores of all subjects of the present study are 
shown. Four of the healthy control subjects (group I) had a lymphocytic focus score > 1. 
Moving the focus score threshold form >1 to >2, as has recently been proposed [8], 
still results in 3 misclassifications of group I subjects, but also in 2 false-negative results 
in SS patients (group II). 
Classification results in subjects of group Ш, IV, and V. Table 4 shows group 
means and standard deviations for lymphocytic focus scores, quantitative 
immunohistologic parameters, and absolute and relative serum immunoglobulin 
concentrations. The differences in LSG immunoglobulin-class distribution between the 
patients with SS and those with probable SS (groups II and III) on the one hand, and the 
patients with KCS (group IV) and those with RA (group V) on the other hand, were far 
more striking than were the differences in serum immunoglobulin concentrations. 
In group III, the "Í^ IgA <70" criterion confirmed the diagnosis SS in all cases, and 
the "DF-score less than -2" criterion confirmed the diagnosis in 10 of 11 cases (91%). 
The "%IgM >10" criterion, Speight and coworkers' scheme [27], confirmed the 
diagnosis SS in 8 of 11 (73%). With regard to DF-scores, %IgA-, %IgG- and %IgM-
containing plasma cells, no significant differences between the 32 patients with primary 
and the 14 patients with secondary SS were found (P>0.05). 
Concerning the aforementioned immunohistologic parameters, no significant 
TABLE 4 
Comparison of labial salivary gland (LSG) biopsy findings and serum immunoglobulin levels in 
all groups of study subjects". 
LSG feature 
No evaluated 
Ig total 
%lgA 
%lgG 
%IgM 
Focus score 
DF score 
Serum value 
No evaluated 
IgA (gm/hter) 
IgG (gm/liter) 
IgM (gm/liter) 
%IgA 
%IgG 
%lgM 
Group 1, 
mean (SD) 
80 
20 5 (9 3)t 
88 3 (7 7)t 
8 3 (6 l)t 
3 4 (3 8)t 
0 2 (0 6)t 
0 36 (0 97)+ 
-ND 
ND 
ND 
ND 
ND 
ND 
Group 11, 
mean (SD) 
40 
80 5 (35 6) 
41 3(17 2) 
33 5(13 3) 
25 1(22 1) 
3 9 (2 0) 
- 4 77 (1 57) 
39 
2 9(1 5) 
18 2 (8 6) 
2 3(1 5) 
12 8 (5 9) 
75 8(10 5) 
11 4(9 4) 
Group HI . 
mean (SD) 
I I 
64 3 (58 9)t 
48 1 (17 0) 
30 5(15 8) 
21 4(19 1) 
2 8(1 2) 
- 4 10 (2 00) 
11 
3 5(1 9) 
20 7(12 9) 
1 7(1 1) 
14 3(5 1) 
78 4 (5 7) 
7 3 (3 6) 
Group IV, 
mean (SD) 
36 
21 7(10 l)t 
82 8(11 5)t 
12 8 (9 0)+ 
4 3 (4 6)t 
0 1 (0 2)t 
- 0 38(1 47)t 
34 
2 2(1 1) 
12 4(3 8)? 
2 0(1 2) 
13 4(4 9) 
74 6 (7 0) 
12 0(6 4) 
Group V, 
mean (SD) 
18 
23 5 (7 8)+ 
86 5 (9 4)t 
8 3 (5 l)t 
5 3 (6 l)t 
1 1 (0 9)t 
0 25 (0 98)t 
17 
2 9 (15 ) 
11 7 (2 9)§ 
1 2 (0 6)§ 
I7 7(5 6)i| 
74 7 (6 3)§ 
7 6 (2 8) 
* Ig total for LSG biopsy = total number of IgA-, IgG-, and IgM-containing plasma cells per 0 04 mm: of tissue See Table 2 for other definitions 
and Table I for description of groups 
t Ρ < 0 001 versus group II Sjogren's syndrome (SS) patients, by Mann-Whitney U test 
tOOl < Ρ < 0 05 versus group II SS patients, by Mann-Whitney U lest 
§ 0 001 < Ρ < 0 01 versus group II SS patients, by Mann-Whitney U test 
differences between SS patients with and without serum autoantibodies (ANA, RF, anti-
SS-A, anti-SS-B) were found (P>0.10). The total number of immunoglobulin-containing 
plasma cells/0.04 mm2 LSG tissue in SS patients with serum anti-SS-B (mean ± SD 
101.2±41.5) was significantly greater (P=0.003) than that in SS patients without serum 
anti-SS-B (64.3±22.8). This difference was mainly caused by the significantly greater 
(P=0.006) numbers of IgG-containing plasma cells in the former SS group. In primary 
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SS, the total number of immunoglobulin-containing plasma cells (86.3±37.1) was 
significantly greater (P=0.002) than that in secondary SS patients (51.8±21.8). 
In group IV, the diagnosis of SS was made in 7 of 36 patients using the "%IgA <70H 
criterion, in 6 of 36 patients using the "DF-score less than -2" criterion, in 8 of 36 
patients using the "DF-score less than -1.19" criterion, and in 2 of 36 using the "%IgM 
> 10" criterion (Table 3). Xerostomia or salivary gland swelling was present in 6 
(85.7%) of the 7 KCS patients with abnormal immunohistologic findings (DF-score less 
than -2 and/or %IgA <70), as compared to 16 (55.2%) of the 29 with normal 
immunohistologic findings. At the time of LSG biopsy, a diagnosis of "possible SS" 
based on KCS and serologic abnormalities [29] (increased serum IgA, IgG, or IgM, 
and/or autoantibodies) was present in all (100%) of the 7 KCS patients with abnormal 
immunohistologic findings, compared with 10 (40.0%) of the 25 with normal 
immunohistologic findings. Due to incomplete serologic evaluation, 4 patients (numbers 
136, 139, 151, and 153) were excluded from this analysis. 
Two patients in the group with abnormal immunohistologic findings (patients 164 and 
165) had autoantibodies against SS-B in their serum, and in patient 165, biopsy of a 
swelling of the palate revealed a benign lymphoepithelial lesion of the palatal minor 
salivary glands, which is highly suggestive of SS [35]. KCS patients with abnormal 
immunohistologic findings in LSGs also had a significantly higher level of IgG in their 
serum (P=0.0003). 
Evaluation of the case records revealed that all 29 patients with normal 
immunohistologic findings were discharged from followup because of the absence of 
complaints or disappearance of previously encountered serologic abnormalities. Therefore, 
the initial clinical diagnosis of "possible SS" was rejected in all 10 KCS patients with 
normal immunohistologic findings on LSG biopsy. 
Two patients with abnormal immunohistologic findings were lost to followup. 
The remaining 5 are still under medical care, with persistence of sicca symptoms and 
serologic abnormalities. In patient 145, primary biliary cirrhosis was subsequently 
diagnosed. Patient 147 has become ANA positive and has developed xerostomia and 
salivary gland swelling. In patiens 158, who had arthralgias, vasculitis, and alveolitis, 
sarcoidosis was subsequently diagnosed based on radiographic evidence of mediastinal 
enlargement, granulomatous lesions on liver biopsy, and elevation of serum levels of 
angiotensin-converting enzyme. However, no granulomas were found in the LSG biopsy. 
None of the group V patients had a DF-score under -2, and only 1 (patient 177) had 
%IgA <70. A focal lymphocytic adenitis of the LSGs was present in 16 of 18 (88.9%), 
and 8 of 18 (44.4%) had a lymphocytic focus score >1 (Table 3). Ophthalmologic 
examination revealed KCS in 3 RA patients (patients 168, 174, and 175): 2 had a 
lymphocytic focus score > 1 , and in the third, the LSG tissue was completely normal. 
None of the 3 RA plus KCS patients had abnormal immunohistologic findings. It should 
be emphasized that none of these patients complained of dry eyes or dry mouth, even 
when carefully questioned. 
In groups II and III, 6 patients with secondary SS associated with RA were included 
(patients 91, 100, 101, 103, 128 and 131) (Table 2). All these patients had severe sicca 
symptoms and were classified as having SS with the "DF-score less than -2" and the 
"%IgA <70" criteria. 
Reproducibility. Among the total of 120 diagnoses, there were 4 (3.3%) diagnostic 
discrepancies between observers when the" DF-score less than -2" was used, and 2 
(1.7%) when the "%IgA <70" was used. Diagnostic discrepancies occurred only in cases 
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where the DF-score or %IgA was near the diagnostic threshold. The two-way analysis of 
variance revealed that there was a slight, but not very significant, systematic observer 
effect (P>0.01) in the quantitative immunohistologic parameters. Incorporating this 
systematic effect in the measurement error gave a reliability of at least 92%. 
Discussion 
In the present study a new, more simple univariate criterion (%IgA <70) as well as a 
refined threshold value for the DF-score (DF-score less than -2), to discriminate between 
healthy controls and SS patients were obtained. The "DF-score less than -2" criterion has 
the same specificity as the "%IgA <70" criterion (98.8%), but its sensitivity (97.5%) is 
slightly higher than that of the H%IgA <70" criterion (95.0%). 
In contrast to 100% specificity and 100% sensitivity reported by Speight et al [27] for 
their "%IgM > 10" criterion, we found it to be 93.7% specific and only 70% sensitive. 
The low sensitivity of the "%IgM > 10" criterion was further confirm«! in our test set 
(group III patients). Application of the criterion in this group resulted in only 73% of SS 
classifications, whereas the "%IgA <70" criterion confirmed all cases of SS the "DF-
score less than -2" criterion confirmed 91% of the cases. 
Speight et al [27] found high numbers of false positives when they applied the "DF-
score less than -1.19" criterion in their control group, which mainly consisted of tissues 
obtained postmortem. The high rate of false-positives was largely attributable to very high 
percentages of IgG-containing plasma cells in the LSG from the control subjects, which 
other investigators have not found, either in minor or major salivary glands [36-39]. The 
most likely explanation for this discrepancy is leakage of serum proteins in the plasma 
cells, which can occur postmortem as well as in poorly fixed tissue [40]. Furthermore, 
the use of a suboptimal fixative and a different immunohistologic procedure may partly 
explain the differences in % IgG-containing plasma cells [41,42]. In a previous study, we 
demonstrated that plasma cell counting can be performed accurately by independent 
observers with excellent reproducibility, provided that salivary gland tissue is fixed in 
formol sublimate and a PAP/DAB staining procedure is used [42]. The present study, in 
which these fixation and staining conditions were used, demonstrated 97% reproducibility 
of the immunohistologic diagnoses by independent observers. 
In our previous study [26], we suggested that, because of its high sensitivity, use of 
the DF-score criterion would result in a reduction of the large numbers of false- negative 
diagnoses that have been described in patients with clinical and/or serologic features 
suggestive of SS, but without a lymphocytic focus score > 1 on LSG biopsy [9-15]. The 
present study convincingly demonstrates the validity of this assumption and discloses for 
the first time that increased relative numbers of IgG- and IgM-containing plasma cells in 
LSGs are not necessarily related to the presence of a grade IV adenitis. 
There is growing evidence that exocrine glands of SS patients are a site of В cell 
activation and autoantibody synthesis, with RF and anti-La/SS-B specificity [43,44]. It has 
been shown that, in comparison with their sera, the saliva of patients with SS is enriched 
with anti-La/SS-B antibodies and that these autoantibodies could be found in saliva of SS 
patients who do not have detectable levels of anti-La/SS-B in the serum [44]. These 
findings demonstrated that autoantibody synthesis is more a reflection of local, rather than 
systemic, В cell activation. Our observation that the group of SS patients with serum anti-
La/SS-B had significantly greater numbers of immunoglobulin- containing plasma cells 
than did the group of SS without detectable serum anti-La/SS-B, suggests that presence of 
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this autoantibody in the serum is related to the level of В cell activation in LSG tissue. 
Such a relationship was not found for ANA, anti-Ro/SS-A, and RF. 
The false-positive diagnosis of SS in the sarcoidosis patient with KCS and xerostomia 
may been a chance occurrence, since a subject in the control group also had a false-
positive diagnosis of SS. Alternatively, this misclassification might be related to the В 
cell hyperreactivity characteristic of sarcoidosis [45], which can mimic the 
immunohistologic features of SS in LSGs. A systematic immunohistologic study of LSGs 
of patients with sarcoidosis is necessary to solve this question. 
Correct diagnostic interpretation of a grade IV lymphocytic adenitis of LSGs from 
patients with connective tissue diseases remains a big problem for the pathologist as well 
as the clinician. This type of adenitis has been described in patients with connective tissue 
diseases in whom SS was not suspected [6,9,18,46]. According to the criteria described 
by Daniels and Talal [29], all these patients should be diagnosed as having secondary SS 
because they meet the 2 criteria of connective tissue disease plus lymphocytic focus score 
>1 on LSG biopsy. However, Lindahl and Hedfors [18] demonstrated in a prospective 
study that a lymphocytic adenitis with a focus score > 2 was present in IS of 80 patients 
who had a connective tissue disease but did not have sicca symptoms at the time of LSG 
biopsy or even after a followup period of 4 years. 
To our knowledge, ours is the first study that demonstrates the existence of 2 
subgroups among RA patients with grade IV adenitis on LSG biopsy. The first subgroup 
consists of those with a DF-score less than -2 and %IgA <70 on LSG biopsy, as seen in 
patients with primary SS as well as in patients with secondary SS associated with other 
connective tissue diseases. The second subgroup consists of RA patients with a DF-score 
greater than -2 and %IgA >70. Based on the absence of clinical suspicion of SS, the 
absence of KCS, and the absence of the highly sensitive immunohistologic features of SS 
in the LSG biopsy specimen, we concluded that the second group of RA patients does not 
have secondary SS, despite the presence of grade IV lymphocytic adenitis. Since the 45% 
prevalence of grade IV adenitis in LSGs from our 18 RA patients without clinical and 
immunohistologic evidence of SS is significantly higher than the 5%-10% prevalence in 
the normal population [16,17], we conclude that this adenitis is related to RA, but arises 
from pathophysiologic mechanisms other than those which produce the same type of 
adenitis in patients with primary and secondary SS. Our recent preliminary observations 
of nuclear accumulation of La/SS-B, with localization of La/SS-B in the cytoplasm, either 
diffusely and/or along the membranes of the acinic cells of LSGs from patients with 
primary or secondary SS [47], further support this hypothesis. This pattern of La/SS-B 
expression was not found in LSGs from non-SS patients, including RA patients with 
grade IV lymphocytic adenitis in the LSG biopsy tissues [47]. 
The results of the present study unequivocally demonstrate that the presence of 
decreased percentages of IgA-containing plasma cells due to strongly increased 
percentages IgM- and/or IgG-containing plasma cells is a much more reliable and 
consistent feature of SS than is either the serologic level of these immunoglobulins or the 
widely accepted grade IV lymphocytic adenitis on LSG biopsy. We propose that our 
quantitative immunohistologic diagnostic criteria should be included in the diagnostic 
evaluation for SS. 
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Abstract 
Aims: To determine the prevalence of plasma cell monotypia in labial 
salivary gland tissue of patients with and without Sjogren's syndrome, and to 
evaluate its relation to the development of systemic monoclonal lymphoproliferative 
disorders. 
Methods: A quantitative immunohistological study was performed on labial 
salivary glands of 45 patients with Sjogren's syndrome, 18 rheumatoid arthritis 
patients without Sjogren's syndrome, and 80 healthy controls. In none of the 
patients with Sjogren's syndrome was there evidence of systemic monoclonal 
lymphoproliferative disease at the time of biopsy. 
Results: Monotypic plasma cell populations, defined by a kappa:lambda 
ratio of ¿ 3 , were only observed in older patients (above 43 years) with Sjogren's 
syndrome. In almost all these patients monotypic plasma cell populations were 
present in multiple labial salivary gland tissues and the IgM/kappa monotypia was 
observed most frequently. The prevalence of monotypic plasma cell populations in 
the group with Sjogren's syndrome was 22% (10/45) and there was no significant 
predilection for primary Sjögrgen's syndrome. Of special clinical interest was the 
observation that progression into systemic monoclonal lymphoproliferative disease 
had occurred exclusively in this subgroup of patients with Sjogren's syndrome with 
a prevalence of 30% (3/10). 
Conclusion: Quantitative immunohistological examination of labial salivary 
gland tissues provides pathologists with a simple method to select those patients with 
Sjogren's syndrome who have an increased relative risk at the time of biopsy to 
develop benign or malignant lymphoproliferative disorders. 
Introduction 
Sjogren's syndrome has often been regarded as a link in the spectrum between 
autoimmune disease and lymphoproliferative disorders [1,2,3]. Polyclonal B-cell 
activation, characterised by hypergammaglobulinemia and autoantibody formation, such 
as rheumatoid factors, antinuclear antibodies, and antibodies to Ro/SS-A and La/SS-B, is 
a common finding in Sjogren's syndrome [2,4,5,6,7]. It is well known that benign or 
malignant systemic monoclonal gammopathy, or malignant lymphoma, may evolve from 
a polyclonal lymphoproliferative process in Sjogren's syndrome [3,8,9]. An 
epidemiological study has shown that the relative risk of developing malignant lymphoma 
in Sjogren's syndrome is about 44 times higher than in the normal population [10]. In 
this study the risk of malignant lymphoma was similar for primary Sjogren's syndrome 
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and secondary Sjogren's syndrome, although other investigators believe malignant 
lymphoma to be more common in primary Sjogren's syndrome [3]. 
Although a sudden decrease in serum immunoglobulin concentration has been 
recognised as a portent of malignant transformation [2,3,11], when Sjogren's syndrome is 
diagnosed it is not possible to detect patients prone to such a transformation. 
Much more promising with regard to predicting malignant transformation in such 
patients were the observations that extra salivary gland non-Hodgkin's lymphomas 
occurred exclusively in patients with Sjogren's syndrome and a myoepithelial sialadenitis 
of the major salivary glands with monotypic B-cell proliferation areas, but not in those 
with polytypic B-cell proliferation areas [11,12]. However, these very interesting findings 
are of relatively little clinical importance, as the labial salivary gland tissue biopsy 
specimen is much more widely used to diagnose Sjogren's syndrome than the major 
salivary gland biopsy specimen. 
In a recent study monoclonal plasma cell populations, defined by a kappa:lambda 
ratio of ¿ 3 , have been demonstrated in labial salivary gland tissues of more than 50% of 
patients with Sjogren's syndrome with concomitant monoclonal cryoglobulinemia [13]. 
However, findings from systematic studies on the prevalence of monotypic 
plasma cell populations in the labial salivary gland tissues of patients with Sjogren's 
syndrome without systemic monoclonal lymphoproliferative disorders at the time of 
biopsy, and their association with progression into the latter disorders, have never been 
published. 
Methods 
Labial salivary gland tissue biopsy specimens from 143 subjects were used (table 
1). Group I comprised 80 healthy control subjects free of systemic diseases, who 
underwent intraoral surgery for cosmetic or preprostetic purposes; group II comprised 18 
patients with rheumatoid arthritis (RA) without sicca complaints, who were willing to 
undergo a lip biopsy. Both served as control groups. Group III consisted of 45 patients 
with Sjogren's syndrome, 35 with primary Sjogren's syndrome and 10 with secondary 
Sjogren's syndrome. All patients with RA fulfilled the criteria defined by the American 
Rheumatism Association [14]. The diagnosis Sjogren's syndrome was based on the 
presence of ophthalmologically confirmed keratoconjunctivitis sicca [15], and a grade Г 
focal sialadenitis based on the scale of Chisholm and Mason [16], corresponding with 
lymphocytic focus score of more than one lymphocytic focus per 4 mm2 labial salivary 
gland tissue. More relevant clinical information about the patients is given in table 1. 
All labial salivary gland tissue biopsy specimens were obtained using the 
horizontal incision technique described by Greenspan et al. [17]. Informed consent was 
obtained. None of the subjects had evidence of a systemic benign or malignant 
monoclonal disorder or malignant lymphoma at the time of labial salivary gland tiissue 
biopsy. 
All biopsy specimens were fixed in a formol sublimate solution [18,19] and 
embedded in paraffin wax. Histological examination and lymphocytic focus scoring were 
performed on hematoxylin and eosin stained sections. In addition, serial 5 μιη sections 
were stained with a peroxidase-antiperoxidase diaminobenzidine (PAP/DAB) technique to 
visualize IgA, IgG, IgM, kappa, and lambda containing plasma cells. Technical details of 
the PAP/DAB technique are summarised in table 2. In cases where monoclonicity of the 
plasma cellular infiltrate was suspected on the basis of the immunoperoxidase staining 
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TABLE 1 
Clinical details of subjects studied. 
GROUP NUMBER N DIAGNOSIS 
(mean age, 
range) 
I 80 Healthy controls: Intraoral surgery for 
(37.7 years cosmetic or preprosthetic purposes; no 
0-78 years) evidence of systemic disease. 
II 18 Rheumatoid arthritis: volunteers 
(S8.6 years without subjective ocular or oral 
42-78 years) dryness, or salivary gland swellings, 
clinically not suspected of having 
Sjogren's syndrome. 
III 45 Sjogren's syndrome: keratoconjunctivitis sicca,* 
(SO.S year focal lymphocytic adenitis of the labial 
14-76 years) salivary glands with a lymphocytic focus 
score of > 1, and serologic abnormalities.** 
Xerostomia was present in 43/45 patients; 
35 patients had primary Sjogren's syndrome, 
10 had secondary Sjogren's syndrome: 4 with 
rheumatoid arthritis, 2 with mixed connective 
tissue disease, 2 with systemic sclerosis, 
1 with primary biliary cirrhosis, and 1 with 
chronic discoid lupus erythematosus. 
^Examination through slit lamp and at least two tests positive of the following: Schirmer's test 
< 5 mm/5min, van Bijsterveld's score of >3, tear break up time of < 10 seconds, decreased 
tear lysozyme or lactoferrin concentration. In five patients only Schirmer's test was performed. 
"Increase in serum IgA, serum IgG, or serum IgM, and/or presence of autoantibodies 
(rheumatoid factor and/or antinuclear antibody and/or anti-SS-A and/or anti SS-B). 
results, double immunofluorescence labelling with antibodies against heavy and light 
chains (IgA/kappa, IgA/lambda, IgG/kappa, IgG/lambda, IgM/kappa, and IgM/lambda) 
was performed on 5 μτη serial paraffin wax sections. 
The following five quantitative immunohistological parameters were obtained 
from measurements in 30 to 40 systematically sampled test fields of 0.04 mm2: the mean 
numbers of IgA, IgG, IgM, kappa, and lambda containing plasma cells per 0.04 mm2 
labial salivary gland tissue. From these parameters the percentages of IgA, IgG, IgM, 
and kappa containing plasma were calculated and will be further designated as %IgA, 
%IgG, %IgM and % kappa. The procedure for quantification of positive plasma cells and 
tissue sampling has been described in detail elsewhere [20]. 
The following serological tests were performed in patients of groups Π and Ш: 
immunoelectrophoresis, serum IgA, IgG, and IgM concentration (radial immunodiffusion 
or nephelometry), presence and type of paraproteins, cryoglobulins, rheumatoid factor 
(Rose-Waaler test), antinuclear antibodies (indirect immunofluorescence on frozen mouse 
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TABLE 2 
Immunoperoxidase procedures used. 
1. Dewaxing and rehydration 
2. Removing of mercury pigment by immersion in Lugol's iodine (S min) 
3. Blocking of endogenous peroxidase in methanol containing 1% 
hydrogen peroxide (30 min) 
4. Preincubation with normal swine serum (20 min) 
5. Incubation with diluted monospecific antisera against IgA (1/800), IgG 
(1/200), IgM (1/800), kappa (1/2400) and lambda (1/2400) (1 hour) 
6. Incubation with diluted swine anti-rabbit serum (1/20) (30 min) 
7. Incubation with diluted rabbit PAP complex (1/800) (20 min) 
8. Development of peroxidase with diaminobenzidine and hydrogen 
peroxide (5 min), intensified with CuS04 (1 min) 
9. Counterstain with Mayer's haematoxylin, dehydrate and mount in DPX 
Antisera diluted in phosphate buffered saline (pH 7.4) containing 1% bovine serum albumine; 
Optimal dilutions found by chess board titration; Incubations at room temperature. All antisera 
were purchased from Dakopatts, Denmark. Specificity of all antisera was confirmed by 
appropriate laboratory tests and on monoclonal plasma cells in bone marrow biopsy specimens 
obtained from related myeloma patients. 
liver sections), anti-SS-A and anti-SS-B (western blotting). 
In statistical analyses % kappa was used instead of kappa:lambda ratio as the 
former looks like much more a normally distributed variable due to the absence of 
skewness. Student's t-test for unpaired observations or Chi2 test were used to compare 
histological, immunohistological, and serological parameters, and the clinical course of 
different groups. 
Details of clinical follow up were obtained from the case records of the patients 
with Sjogren's syndrome. 
Results 
Quantitative study. Five quantitative immunohistological parameters are used to 
quantify the composition of the plasma cellular infiltrates in labial salivary gland tissue. 
These five parameters are: the mean %IgA, %IgG, %IgM, % kappa containing plasma 
cells and the mean number of light chain containing plasma cells per 0.04 mm2 labial 
salivary gland tissue (kappa-(-lambda). These five parameters in patients with RA (group 
II) were not significantly (P>0.05) different from those of the group of healthy controls 
(group I); these five parameters in patients with Sjogren's syndrome (group III) differed 
significantly from those of healthy controls and patients with RA (table 3). There were 
no significant differences (P>0.10) between primary Sjogren's syndrome and secondary 
Sjogren's syndrome with regard to %IgA, %IgG, %IgM and %kappa. In primary 
Sjogren's syndrome the numerical density of light chain containing plasma cells 
(kappa+lambda) was significantly higher than in secondary Sjogren's syndrome 
(P=0.003) (table 3). 
Figure 1 shows % kappa in the labial salivary gland tissue biopsy specimens of 
all subjects of the three groups. The normal range of % kappa (determined in groups I 
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TABLE 3 
Comparison of quantitative immunohistological results in labial salivary gland tissue of patients 
and controls. 
Parameter 
Xkappa 
к • I 
XlgA 
XI gG 
XI gM 
Group I 
(N=80) 
mean (SD) 
59.1 (4.3) 
22.0 (10.0) 
88.3 (7.7) 
8.3 (6.0) 
3.4 (3.8) 
Group II 
(N=18) 
mean (SD) 
59.1 (4.9) 
24.9 (8.1) 
86.4 (9.4) 
8.3 (5.1) 
5.3 (6.1) 
Group III 
(N=45) 
mean (SD) 
66.7 (9.9)# 
80.1 (41.0)* 
42.2 (17.1)* 
33.6 (13.3)* 
24.3 (21.4)* 
Primary ss 
(N=35) 
mean (SO) 
66.7 (10.1) 
86.9 (43.1) 
43.1 (17.9) 
35.2 (13.7) 
21.7 (21.3) 
Secondary SS 
(N=10) 
mean (SO) 
66.9 (10.0) 
56.4 (20.0)3 
39.1 (14.2) 
27.7 (10.6) 
33.3 (20.2) 
% kappa, %IgA> %IgG, %IgM = percentage of kappa, Ig A, IgG, and IgM containing plasma 
cells in the labial salivary gland tissue; к + 1 = total number of kappa and lambda containing 
plasma cells per 0.04 mm2 labial salivary gland tissue; *Significantly different from group I and 
II: p<0.001, by Student's t-test; ^Significantly different from group I (p<0.001) and from group 
II (p=0.02), by Student's t-test; ©Significantly different from primary Sjogren's syndrome 
(p=0.003), by Student's t-test. 
100 
? 
Q_ 
Patients group number 
Fig. 1. Percentages of kappa containing plasma cells of all subjects in this study. Dotted 
horizontal lines define the pooled 99.8% confidence interval (mean ± 3xSD) of the control 
groups I and II. Ten patients with Sjogren's syndrome were beyond this confidence interval. 
and II and set at the mean ± 3 standard deviations) was 4S.9%-72.3%. In 10 patients 
with Sjogren's syndrome %kappa was out of the normal range (figure 1). All these 
patients had an excess of kappa containing plasma cells, with at least 75.5% kappa 
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TABLE 4 
Histological, immunohistological and serological results in patients with Sjogren's syndrome 
compared with abnormal (group III-A) and normal (group IH-B) percentage kappa containing 
plasma cells in labial salivary gland tissue 
LSG tissue parameter: 
Xkappa 
к + I 
XI gA 
XI gG 
XI gM 
LFS 
Serin Ig: 
IgA (gm/D 
IgG (gm/l) 
IgH (gm/l) 
Incidence of: 
Sal. gland swelling 
Cryoglobulinemia 
Rheunatoid factor 
Ant ι nuclear antibody 
Anti-SS-A 
Antl-SS-B 
Serin IgG >13.3 gm/l 
(¡roup III-A 
(N-10) 
mean 
81.4 
7V.1 
28.4 
23.5 
(SO) 
(6.2) 
(32.0) 
(14.4) 
(15.4) 
51.7 (25.3) 
5.3 
2.2 
12.4 
2.8 
4/10 
5/10 
3/7 
6/10 
4/10 
4/10 
4/10 
(2.1) 
(0.9) 
(5.0) 
(1.3) 
Сгоцр III-B 
(N=35) 
mean 
62.5 
80.4 
47.1 
36.4 
16.5 
3.4 
3.3 
21.1 
2.2 
13/35 
2/27 
23/34 
26/35 
9/32 
15/32 
28/35 
(SD) 
(5.9) 
(43.6) 
(14.5) 
(11.4) 
(11.9) 
(1-8) 
(1.7) 
(9.4) 
(1.5) 
Ρ 
Student's 
t-test 
n.r. 
0.93 
0.0001 
0.005 
0.002 
0.006 
0.012 
0.0005 
0.30 
Chi square 
test 
0.87 
0.003 
0.22 
0.38 
0.48 
0.70 
0 03 
LSG = labial salivary gland, к + 1 = total number of kappa and lambda containing plasma cells 
per 0 04 mm2 labial salivary gland tissue, %kappa, %IgA, %IgG, %IgM are percentages of 
kappa, IgA, IgG, and IgM containing plasma cells in labial salivary gland tissue; LFS = 
lymphocytic focus score, Sal gland swelling = salivary gland swelling, η r = not relevant, as 
% kappa was used to select the two subgroups of Sjogren's syndrome patients 
containing plasma cells in the labial salivary gland tissue (range %kappa: 75 5%-91.1%). 
A % kappa of >75 was found in eight of 35 patients with primary Sjogren's syndrome 
and in two of 10 with secondary Sjogren's syndrome. The difference in prevalence of 
%kappa > 7 5 between primary Sjogren's syndrome and secondary Sjogren's syndrome 
was not significant ( P = 0 8). The population of patients with Sjogren's syndrome (group 
III) was divided in two subpopulations, group III-A with % kappa >75 and group III-B 
with %kappa < 7 5 
Table 4 shows that patients with abnormal % kappa also had significantly higher 
%IgM (P=0.002), significantly lower %IgA and %IgG (P<0.005), and a significantly 
higher lymphocytic focus score (P=0.006) There was no significant difference (P=0.93) 
between these two subgroups of Sjogren's syndrome with regard to the total 
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numerical density of plasma cells (kappa+lambda) in the labial salivary gland tissue 
(table 4). The relation between high percentages of kappa and IgM containing plasma 
cells is clearly demonstrated in the scatter diagram of figure 2. 
Table 4 shows that the serum IgA and IgG concentrations in the patients with 
Sjogren's syndrome of group III-A were significantly lower than in the patients in in 
group III-B, with Ρ values of 0.01 and 0.0005 respectively. Furthermore, polyclonal 
cryoglobulinemia was found significantly more often in patients with Sjogren's syndrome 
of group III-A (P=0.003). The prevalence of normal serum IgG titres (IgG < 13.3 gm/1) 
was significantly higher in group III-A than in group III-B patients (P=0.03). 
The scatter diagram in figure 3 shows that all patients with Sjogren's syndrome 
with % kappa ^75 (group III-A) were older than 43 years. Under the assumption that 
there is no age predominance for this phenomenon one would expect that four of the 18 
patients with Sjogren's syndrome younger than 43 years would have a %kappa ^75. 
Group II patients had the same age distribution as group III-A patients, but in the former 
group none of the patients had abnormal % kappa values, despite the presence of 
lymphocytic adenitis in 89% of them (table 5). 
Qualitative study. In the 10 patients with Sjogren's syndrome with % kappa 
¿75 (group III-A) the results of immunoperoxidase staining of the labial salivary gland 
tissue biopsy specimens gave rise to suspicion of monotypic plasma cell populations 
within the infiltrate. In eight of these patients kappa containing plasma cells predominated 
throughout all the glands of the biopsy specimen. 
TABLE 5 
Mean ages and percentage of kappa containing plasma cells in labial salivary gland tissue in all 
patients and controls. 
GROUP 
I (Hea 
II (RA) 
I+II 
I HA (SS, 
HIB (SS, 
III (SS, 
Ithy controls) 
»cappa >75) 
Xkeppa <75) 
whole group) 
Ν 
80 
IB 
98 
10 
35 
45 
Mean age 
(years) 
37.7 
58.6 
41.6 
59.8 
47.8 
50.5 
(range) 
(0-78) 
(42-78) 
(0-78) 
(44-73) 
(14-76) 
(14-76) 
Mean Xkappa (range) 
59.1 (50.5-69.2) 
59.1 (50.5-69.0) 
59.1 (50.5-69.2) 
81.4 (75.5-91.9) 
62.5 (50.9-72.2) 
66.7 (50.9-91.9) 
RA = rheumatoid arthritis; SS = Sjogren's syndrome; % kappa = percentage of kappa 
containing plasma cells in labial salivary gland tissue. 
In one patient the biopsy specimen, comprising four glands, had a predominance 
of IgG/kappa containing plasma cells in two glands; in the other two glands there was no 
suspicion of monotypic plasma cells. In another patient the biopsy specimen, consisting 
of nine glands, showed predominance of IgA/kappa containing plasma cells in one gland 
and predominance of IgM/kappa containing plasma cells in the other glands. 
In seven of the 10 patients with Sjogren's syndrome with %kappa of ¿75 the 
labial salivary gland tissue was available for double immunofluorescence labeling. This 
confirmed the presence of monotypic plasma cell populations within the infiltrates in all 
seven cases. In six cases the monotypic plasma cell populations were of IgM/kappa type 
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TABLE 6 
Serological and immunohistological results of group IH-A. 
Nr 
10 
Age 
(years) 
50 
73 
62 
59 
55 
66 
«4 
69 
49 
71 
ANA 
+· 
+ 
• 
+ 
-
-
-
•f 
+ 
" 
RF 
• 
-
NO 
-
-
ND 
·» 
« 
ND 
e-SS-A 
•f 
-
-
+ 
-
-
-
+ 
-
+ 
SEROLOGY 
a-SS-B 
+ 
• 
• 
+ 
-
• 
* 
+ 
» 
" 
Cryogl 
+ 
+ 
-
• 
-
• 
• 
-
+ 
• 
IgA 
(in 
IgG 
ΙβΗ 
grane/li ter) 
12.5 
7.0 
5.6 
21.8 
9.4 
8.8 
17.7 
13.7 
12.4 
15.3 
Mappa 
80.7 
91.1 
86.3 
91.9 
79.3 
78.8 
76.2 
75.5 
78.9 
π.7 
XI gA 
37.7 
7.0 
16.4 
3.8 
21.9 
36.2 
32.3 
50.2 
18.4 
24.7 
LABIAL ! 
XISG 
29.2 
8.0 
4.2 
32.2 
24.2 
14.8 
24.7 
44.2 
5.7 
47.7 
SALIVARY 
XI gH 
33.1 
85.0 
79.4 
64.1 
53.9 
49.1 
43.1 
5.5 
75.9 
27.6 
GLANDS 
LFS 
2.6 
Nonotyplc Ig 
(Double IF) 
IgA/k I IgM/k 
IgM/k 
IgM/k 
IgM/k 
IgM/k 
IgN/k 
IgM/k 
ND 
ND 
ND 
ANA = antinuclear antibody; RF = rheumatoid factor; a-SS-A = antibodies against SS-Α; a-SS-
B = antibodies against SS-B; Cryogl = cryoglobulinaemia; % kappa, %IgA, %IgG, %IgM = 
percentages of kappa, IgA, IgG, and IgM containing plasma cells; LFS = lymphocytic focus 
score; monotypic Ig = monotypic immunoglobulin; Double IF = double immunofluorescence 
laballing; ND = not done; к = kappa; Normal values are: IgA 0.3-2.5 g/1, IgG 4.7-13.3g/l, 
IgM 0.4-2.4 g/1. Cases 2 and 7 had secondary Sjogren's syndrome. 
and in one case of both IgM/kappa and IgA/kappa (table 6). Serological, histological, 
and immunohistological findings of the 10 patients with Sjogren's syndrome with an 
abnormal % kappa in the labial salivary gland tissue are also shown in table 6. 
Follow up study. Two of the 10 patients with Sjogren's syndrome with an 
excess of kappa containing plasma cells in the labial salivary gland tissue developed 
systemic monoclonal gammopathy with circulating IgM/kappa six months and six years, 
respectively, after the labial salivary gland tissue biopsy had been performed (cases 6 and 
10 in table 6). In both cases the circulating paraprotein was identical with that of the 
immunoglobulin found in the labial salivary gland tissue. In one of these patients Bence 
Jones (kappa) protein was also found in the urine (case 2 in table 6). In a third patient 
(case 10 in table 6) with excess of kappa containing plasma cells in the labial salivary 
gland tissue malignant lymphoma (polymorphic immunocytoma, IgM/lambda) of the lung 
was diagnosed one year after the labial salivary gland tissue biopsy. In this patient, 
however, monotypic IgG/kappa В cell expansion in the labial salivary gland tissue was 
suspected on the basis of the immunoperoxidase staining results. All three patients had 
primary Sjogren's syndrome. 
The median follow up period in the group of 10 patients with Sjogren's 
syndrome with an abnormal % kappa in the labial salivary gland tissue was three years 
(range 1.5-9.5 years). None of the patients with normal % kappa in the labial salivary 
gland tissue had developed systemic monoclonal gammopathy or malignant lymphoma 
after a median follow up period of 4.5 years (range 1-11 years). In the group of patients 
with Sjogren's syndrome with % kappa of ¿75% the disease progressed into a systemic 
monoclonal process or malignant lymphoma significantly more often (P=0.008). 
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Discussion 
The present study shows, for the first time, the occurrence of high percentages of kappa 
light chain containing plasma cells, due to the presence of monotypic plasma cell 
populations, in the labial sdalivary gland tissue of 10 of our 45 (22%) patients with 
Sjogren's syndrome but without evidence of systemic monoclonal lymphoproliferative 
disease at the time of labial salivary gland tissue biopsy. Although systemic 
lymphoproliferative disorders are sometimes considered to be related to primary 
Sjogren's syndrome [3], this could not be validated. Of special clinical interest is our 
observation that progression into systemic monoclonal gammopathy or malignant 
lymphoma exclusively occurred in the subgroup of patients with Sjogren's syndrome with 
monotypic plasma cell populations, defined by a kappa:lambda ratio of ^ 3 . 
Our findings agree with those obtained from immunohistological studies [11,12] 
of the benign lymphoepithelial lesion of the major salivary glands, which is closely 
related to Sjogren's syndrome [21]. These studies showed that extra-salivary gland 
lymphoma occurred exclusively in patients with a benign lymphoepithelial lesion with 
monotypic proliferation areas and not in those with polytypic proliferation areas. 
Myoepithelial sialadenitis (benign lymphoepithelial lesion) of the major salivary glands 
with proliferations of В cells with monotypic cytoplasmatic immunoglobulins has been 
considered to be a neoplastic lesion, and mentioned an early lymphoma [11,12]. 
The monoclonal origin of the monotypic plasma cells in the autoimmune 
sialadenitis has been confirmed by immunoglobulin gene rearrangement studies [22,23]. 
Fishleder et al found in benign lymphoepithelial lesions of parotid and submandibular 
gland, removed two years later from the same patient with Sjogren's syndrome, that the 
rearrangements of the heavy chain and kappa light chain genes were entirely different 
[22], making it highly unlikely that the В cell clone identified in the second lesion 
evolved from the first. Different immunoglobulin gene rearrangements in the same 
patient with benign lymphoepithelial lesions of different major salivary glands have also 
been observed by Freimark et al [23]. We did not perform immunoglobulin gene 
rearrangement studies due to shortage of tissue. However, our observation that multiple 
separated minor salivary glands of a labial salivary gland tissue biopsy specimen are 
populated by monotypic plasma cells of the same isotype (IgM/kappa) or even of 
different isotypes in different glands in one of our patients (IgM/kappa and IgA/kappa) 
supports the hypothesis that monotypic plasma cell populations in the salivary glands of 
patients with Sjogren's syndrome are not the result of a clonal expansion of a single 
neoplastic changed lymphoid stem cell. Our observation of equal mean total number of 
kappa and lambda containing plasma cells per 0.04 mm2 of labial salivary gland tissue in 
the two groups of patients with Sjogren's syndrome also argues against the assumption of 
neoplastic В cell proliferation in patients with monotypic plasma cell populations. More 
convincing support can be found in our observation that an IgM/lambda polymorphic 
immunocytoma of the lung developed in a patient with Sjogren's syndrome with 
predominance of IgG/kappa containing plasma cells in the labial salivary gland tissue. 
In our study all subjects with %kappa>75 were patients with Sjogren's 
syndrome older than 43 years. If there was no age preference for the occurrence of 
monotypic plasma cell infiltrates in patients with Sjogren's syndrome one could expect 
that four of our 18 patients younger than 43 years would also exhibit this phenomenon. 
In group II (patients with RA) the age distribution pattern resembled that of the group 
with Sjogren's syndrome with monotypic plasma cell populations (group III-A). 
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However, none of these patients with RA had a % kappa of ¿75, but about 50% of these 
patients has lymphocytic adenitis with focus score of >1 , mimicking the sialadenitis of 
Sjogren's syndrome. 
All aforementioned observations support the hypothesis that monotypic plasma 
cell populations appear after a latency period in the labial salivary gland tissue and 
probably also in other exocrine glands in some patients with Sjogren's syndrome with an 
initial polytypic plasma cellular infiltrate. This switch from a polytypic into a monotypic 
plasma cell infiltrate in many different glands can not be attributed to neoplastic changes. 
A more likely explanation is that the exocrine glands in a subpopulation of patients with 
Sjogren's syndrome are homed by primitive В cells, which are liable to homeostatically 
regulated clonal expansions after prolonged antigenic stimulation by modified 
parenchymal cells in the target organs, and that this phenomenon is accompanied by an 
increased risk to develop systemic monoclonal lymphoproliferative disorders. On the 
basis of several studies В lymphocytes expressing CD5 antigen which are related to 
autoantibody production and monoclonal expansions [24,25,26], are a serious candidate. 
In summary, the results of the present study and those of Schmid et al [11] show 
that patients with Sjogren's syndrome with monotypic В cell populations in their salivary 
glands are at increased risk of developing systemic monoclonal lymphoproliferative 
disorders. Knowing that the relative risk of all patients with Sjogren's syndrome of 
developing malignant lymphoma is about 44 times higher than in the normal population 
[10], it can be assumed that the relative risk of the subgroup of such patients with 
monotypic В cell populations in their salivary glands is considerably higher. We conclude 
that quantitative immunohistological examination of labial salivary gland tissue provides 
pathologists with a simple method to select those patients with an increased relative risk, 
at the time of labial salivari gland tissue biopsy to develop benign or malignant 
lymphoproliferative disorders. 
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Abstract 
Objective. Salivary glands of patients with Sjogren's syndrome (SS) have 
been shown to be a site of anti-La(SSB) antibody production. The aim of the present 
study was to search for differences in the inununoreactivity pattern of the La(SSB) 
antigen in labial salivary gland tissue between SS- and non-SS patients which may 
explain the local antigen driven anti-La(SSB) response. 
Methods. The inununoreactivity pattern of the La(SSB) antigen was studied 
in labial salivary gland biopsies of б SS patients with and 7 patients without SS and 
in normal tissues obtained at autopsy within two hours after death, using a mouse 
monoclonal antibody directed to La(SSB). 
Results. Patients with SS showed a dramatic accumulation of La(SSB) in the 
nuclei of acinic cells of salivary glands as compared to non-SS patients. In SS 
patients La(SSB) antigen was also detected in the cytoplasm as a diffuse or 
perinuclear staining. Sometimes it was found along the cell membrane of acinic cells 
as well. This aberrant immunostaining pattern of La(SSB) antigen correlated well 
with quantitative immunohistologic abnormalities in the plasma cell population of 
the labial salivary gland tissue, but not with a lymphocytic focus score greater than 
one. 
Conclusion. The accumulation and redistribution of La(SSB) in labial 
salivary glands may be of importance for the pathogenesis of SS, and can also be 
useful in the diagnosis of this disease. 
Introduction 
The La(SSB) antigen is a 47-kD polypeptide associated with small RNA 
molecules in ribonucleoprotein (RNP) complexes [1,2]. The antigen is primarily located 
in the nucleus and to a lesser extent in the cytoplasm [2]. The protein is encoded by a 
single gene on chromosome 2 [3], and its function has been described as a transcription 
termination factor of RNA polymerase III [2]. 
Antibodies directed to the La(SSB) RNPs are very common in patients with 
Sjogren's syndrome (SS) [4-7]. They are found in the serum of 60-90% of patients with 
primary SS, 30-50% of patients with secondary SS, 25-50% of patients with systemic 
lupus erythematosus, but rarely in the serum of patients with other connective tissue 
diseases [4-7]. The presence of anti-La(SSB) autoantibodies in the serum has been 
included in the California criteria for the diagnosis of SS [8]. 
It is well known that exocrine tissues are a site of B-cell activation and 
autoantibody production in SS [9-12]. Furthermore, patients with SS show increased 
numbers of IgG- and IgM-containing plasma cells in their labial salivary gland (LSG) 
tissue [13-15]. Diagnostic criteria for SS based on the latter phenomenon are highly 
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specific and sensitive, as has been demonstrated previously [14,16]. It has also been 
shown that saliva of patients with SS is enriched with anti-La(SSB) antibody as compared 
to the serum [17]. Moreover, anti-La(SSB) antibody can be found in saliva of SS patients 
without detectable anti-La(SSB) activity in the serum [17]. These findings point to the 
possibility that anti-La(SSB) autoantibodies are primarily produced in salivary glands of 
SS patients. The demonstration of anti-La(SSB) antibodies in the cytoplasm of plasma 
cells in LSG tissue, using antibodies directed to private idiotypes of anti-La(SSB) 
antibodies, further supports this suggestion [12]. However, it is still unclear whether 
La(SSB) and autoantibodies directed to La(SSB) play a role in the pathogenesis of SS. 
In the present immunohistologic study the immunoreactivity pattern of La(SSB) 
antigen in LSGs of SS patients was compared to that in non-SS patients. Furthermore, 
the distribution of La(SSB) in various normal tissues was examined. The aim of this 
study was to search for possible differences in the immunoreactivity pattern of the 
La(SSB) antigen between SS and non-SS patients, which might be related to the local 
production and secretion of antibodies to these antigens. Finally, the relationship between 
the La(SSB) immunoreactivity pattern and the distribution pattern of Ig-containing plasma 
cells in LSG tissue was studied. 
Patients and methods 
Subjects. LSG biopsies from six consecutive SS patients, three with primary SS 
and three with secondary SS (two associated with rheumatoid arthritis and one associated 
with systemic sclerosis) were used. All SS patients fulfilled the criteria as described by 
Daniels and Talal [18]. As controls LSG biopsies from seven non-SS patients were used: 
two from patients with rheumatoid arthritis without SS who voluntarily ceded a lip 
biopsy, and five from patients without SS who underwent the biopsy procedure for 
diagnostic purposes. For diagnosis of SS in the LSG biopsy, part of the biopsy specimens 
was fixed in a formol sublimate solution [19,20]. The lymphocytic focus scores [21] 
were determined in haematoxylin and eosin stained sections. Serial 5 μτη sections were 
stained with a peroxidase anti-peroxidase technique using monospecific antibodies 
directed to Ig A, IgG, and IgM. The percentages of IgA-, IgG-, and IgM-containing 
plasma cells were determined according to a procedure which has been described in 
detail elswhere [14,20]. A percentage of IgA-containing plasma cells smaller than 70% 
and/or a DF-score (DF-score = 0.062 χ %IgA - 0.088 χ %IgG - 4.387) smaller than -2 
in the LSG biopsy were considered as diagnostic for SS [16]. This procedure has been 
implemented in the diagnostic evaluation of LSG biopsies in our laboratory. 
Methods. Part of the LSG biopsies were snap frozen in liquid nitrogen. Five μτη 
sections were cut from each frozen tissue specimen, and air-dried over night. A mouse 
monoclonal antibody (MoAb) directed to the La(SSB) antigen (SW5) [22] was used for 
detection of La(SSB) at tissue level in the frozen sections. The sections were stained with 
an indirect immunoperoxidase technique. The sections were fixed in aceton for 10 
minutes and rinsed in phosphate buffered saline (three washes of 5 minutes). SW5 was 
used in a dilution of 1:10, and rabbit-anti-mouse serum in a dilution of 1:80. AH antisera 
were diluted in phosphate buffered saline (PBS) (pH 7.4) containing 1% bovine serum 
albumine. Optimal dilutions were found by chess board titration. The sections were 
incubated with SW5 for 1 hour at room temperature, and with rabbit-anti-mouse serum 
for 30 minutes at room temperature. The incubation steps were followed by three washes 
in PBS of 5 minutes. Controls were performed by replacing SW5 by PBS or by MoAbs 
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directed to two other RNPs which are related to cellular activity, viz. MoAb 2.73 
(dilution 1:100) directed to Ul-snRNP [23] and MoAb 4G3 (dilution 1:100) directed to 
U2-snRNP [24]. Peroxidase was developed with diaminobenzidine and hydrogen peroxide 
for 5 minutes, intensified with CuS04 for 1 minute. No nuclear or cytoplasmatic 
counterstaining was performed in this immunoperoxidase staining procedure in order to 
facilitate the microscopic assessment of La(SSB), Ul-snRNP and U2-snRNP 
immunoreactivity patterns. 
To study the La(SSB) distribution in normal tissues, specimens of liver, spleen, 
pancreas, adrenal gland, lymph nodes, striated muscle, and duodenum, obtained from 
three patients within two hours postmortally at autopsy were used. The cause of death 
was cerebral hemorrhage in all cases and none of them was known to have suffered from 
a systemic autoimmune disease. Frozen sections of these tissue specimens were stained 
with the indirect immunoperoxidase technique as described above. 
Results 
The most striking difference between SS and non-SS patients was the intense 
La(SSB) immunoreactivity in the nuclei of acinic cells in SS patients. Figures 1A and IB 
clearly demonstrate the difference in La(SSB) immunoreactivity between a patient with 
primary SS and a non-SS patient, respectively. Figure 1A shows a high immunostaining 
intensity in the majority of the nuclei of acinic cells, when compared with the acinic cells 
of the non-SS patient (Fig. IB) and the control sections of the same 2 patients which 
were not incubated with SW5 antibody (Figs. 1С and ID). Comparison of Figure IB and 
ID revealed a very weak nuclear La(SSB) immunoreactivity in the acinic cells of a non-
SS patient. There is no difference between primary SS and secondary SS with regard to 
the La(SSB) nuclear immunoreactivity (compare Figs. 1A and IE). 
The immunoreactivity patterns in LSG biopsies of the RA patients without any 
suspicion of SS (Fig. IF) and the control subjects without any systemic connective 
disease (Fig. IB) are essentially the same. With regard to the immunoreactivity of Ul-
snRNP and U2-snRNP, no differences between SS and non-SS patients could be 
observed. In all subjects there is intense nuclear immunostaining of both antigens. 
Figures 2A-2D show the results for U2-SnRNP for the same 4 patients as shown in 
Figures 1A, IB, IE and IF, respectively. 
At a magnification of 1000X the nuclear staining pattern of La(SSB) appears to 
be speckled (Fig. ЗА). In SS patients, the La(SSB) antigen is also present in the 
cytoplasm of acinic cells in either a perinuclear or diffuse granular pattern or along the 
cell membrane of these cells (Fig. ЗА). In such acinic cells a decrease of nuclear 
La(SSB) could be noted (Fig. ЗА). In the non-SS patients no cytoplasmatic localization of 
La(SSB) was observed in the LSG tissue. The typically speckled pattern due to the 
presence of Ul-snRNP and U2-snRNP was restricted to the nucleus in SS as well as in 
non-SS patients (Fig. 3B). 
In Table 1 the La(SSB) immunoreactivity in LSG tissue of all 13 subjects is 
shown in relation to histologic, quantitative immunohistologic, clinical and serologic 
findings. The results indicate that the aberrant immunostaining pattern of La(SSB) in the 
LSG tissue of SS patients is not necessarily accompanied by the presence of serum anti-
La(SSB) and, vice versa, that the presence of anti-La(SSB) in the serum of a non-SS 
patient (patient 10) is not necessarily accompanied by an aberrant immunoreactivity 
pattern of La(SSB) in the acinic cells. 
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Fig. 1. Immunostaining of the La(SSB) antigen in acinic cells of LSGs: 1A-1F are 
microphotographs taken at a magnification of 400X. An intense immunostaining with MoAb SWS 
directed to the La(SSB) antigen can be observed in the majority of nuclei of acinic cells of LSGs 
of a patient with primary SS (IA). In the LSGs of a non-SS patient only a very weak La(SSB) 
immunoreactivity can be observed in the nuclei of acinic cells (IB). Control sections of the 
patients of 1A and IB, which are not incubated with MoAb SWS, do not exhibit any 
immunoreactivity (1С and ID). In a patient with secondary SS and systemic sclerosis there is also 
an intense nuclear immunostaining in a large number of acinic cells (IE). The nuclear La(SSB) 
immunoreactivity of acinic cells in a RA patient without SS (IF) is very weak and does not differ 
from that of the patient shown in IB. 
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Fig. 2. Immunostaining of snRNP-antigens in acinic cells af LSGs: 2A-2D show the 
immunostaining results with MoAb 4G3 directed to U2-snRNP at a maginification of 400X in the 
same 4 patients as demonstrated in 1A, 1С, IE and IF, respectively. In all patients there is an 
intense nuclear U2-snRNP immunoreactivity in all cells and no differences between the patients 
could be observed. 
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Fig. 3. At a magnification of lOOOX the La(SSB) staining pattern in the nuclei of acinic cells of 
SS patients appeared to be speckled (ЗА). In some cells a perinuclear cytoplasmic or more diffuse 
cytoplasmic immunostaining can be observed, accompanied by a decrease of nuclear La(SSB) 
immunoreactivity (arrow) (ЗА). Comparison of ЗА and 3B shows that U2-snRNP antigen is only 
localized in the nuclei of acinic cells (3B) and not in the cytoplasm as is the case with the 
La(SSB) antigen (ЗА). 
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TABLE 1 
Clinical, histologic, immunohistologic, and serologic findings of subjects studied. 
LABIAL SALIVARY GLANDS 
SUBJECT DIAGNOSIS DRY MOUTH LFS XlgA XIgG XIgM DF-score La(SSB) SERUM ANTI La(SSB) 
10 
11 
12 
13 
prim SS 
prim SS 
prim SS 
sec SS-RA 
sec SS-RA 
sec SS-SSc 
RA 
RA 
no CTD 
no CTD 
no CTD 
no CTD 
no CTD 
+ 
+ 
+ 
+· 
+ 
-
-
-
-
-
-
-
5.1 
2.1 
2.7 
1.7 
2.9 
3.2 
1.2 
1.7 
0 
0.2 
0 
0.9 
0 
19 
39 
57 
68 
31 
67 
75 
88 
93 
95 
78 
82 
94 
73 
47 
31 
24 
38 
8 
15 
8 
6 
4 
21 
11 
5 
10 
14 
12 
8 
32 
25 
10 
4 
1 
1 
1 
7 
1 
-9.6 
-6.1 
-3.6 
-2.2 
-5.8 
-1.0 
-1.1 
0.3 
0.9 
1.2 
-1.4 
-0.3 
1.0 
prim SS = primary Sjogren's syndrome; sec SS = secondary Sjogren's syndrome; RA = 
rheumatoid arthritis; SSc = systemic sclerosis; CTD = connective tissue disease; - = not 
present; + = present; A = aberrant; N = normal; LFS = lymphocytic focus score; %IgA, 
%IgG, %IgM = percentage of IgA, IgG, IgM containing plasma cells; DF-score = 
0.062x%IgA-0.088x%IgG-4.387; ND = not done. 
An interesting finding was that 2 patients with RA but without SS had a grade 
IV lymphocytic adenitis of the LSGs, corresponding with a lymphocytic focus score > 1, 
which is suggestive for SS. These patients had normal percentages of IgA-containing 
plasma cells (%IgA >70) and normal DF-scores (DF-score >-2), as well as a normal 
La(SSB) immunoreactivity pattern. In contrast, the 2 RA patients with SS combined 
abnormal immunohistologic findings (%IgA <70 and DF-score <-2) with the aberrant 
immunoreactivity pattern of La(SSB). 
Evaluation of the immunoreactivity pattern of La(SSB) in the normal tissues 
obtained at autopsy revealed an interorgan variation in La(SSB) immunoreactivity pattern. 
The immunoreactivity found in the nuclei of liver, adrenal gland and spleen was much 
higher than in the other tissues. In none of the normal tissue specimens cytoplasmatic 
localisation of La(SSB) was observed. 
Discussion 
The present study demonstrates for the first time, that in patients with primary 
as well as secondary SS there is evidence of La(SSB) antigen accumulation in the nuclei 
of acinic cells of LSGs when compared to non-SS patients. In vitro studies revealed that 
in virally or otherwise transformed cells an up to thirteen-fold increment of the nuclear 
La(SSB) concentration and a redistribution of La(SSB) leading to cytoplasmic and cell 
membrane localisations can be observed [25,26]. Our observations of perinuclear and 
diffuse cytoplasmic deposition of La(SSB) as well as localisation along cell membranes of 
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acinic cells, accompanied by a decrease of nuclear La(SSB), suggest that the in vitro 
observed redistribution also seems to occur in acinic cells of SS patients. The latter 
phenomenon cannot be explained by assuming a diffusion artefact due to the possibly 
loose association of La(SSB) with intracellular structures [2], since cytoplasmic 
localisation of La(SSB) was not observed in normal liver, spleen and adrenal cells, which 
also showed high nuclear La(SSB) immunoreactivity. The Ul-snRNP and U2-snRNP 
antigens did not exhibit such an enhanced nuclear immunoreactivity or cytoplasmic 
localisation in the acinic cells of the LSGs of SS patients. 
Recently, it has been shown that saliva of patients with SS is enriched with and-
La(SSB) antibodies as compared to the serum [17]. Anti-La(SSB) anti-bodies have even 
been found in saliva of SS patients without detectable levels of anti-La(SSB) antibody in 
the serum [17]. The latter finding is supported by our observation that the aberrant 
immunoreactivity pattern of La(SSB) in the acinic cells of SS patients is not necessarily 
associated with the presence of anti-La(SSB) autoantibody in the serum of these patients. 
Moreover, Horsfall et al [12] found anti-La(SSB) idiotype containing plasma cells as well 
as peri-acinar deposition of anti-La(SSB) idiotype antibodies in LSGs of SS patients. In 
these glands the acinic cells were also expressing major histocompatibility complex 
(MHC) class II antigens [12]. 
The aberrant La(SSB) immunoreactivity pattern in LSG tissue of SS patients 
together with the local production and secretion of anti-La(SSB) [12], and the fact that 
various B-cell epitopes reside on the C-terminal half of the La(SSB) antigen [27] support 
the following hypothesis. It is assumed that membrane localization of La(SSB) in SS 
patients might provoke a local La(SSB) antigen-driven immune response. Local secretion 
of cytokines, such as gamma interferon, provokes glandular MHC class II antigen 
expression [28-30], which may enhance the presentation of parts of the La(SSB) antigen 
to the immune system, perpetuating the immune response. The local immune response is 
characterized by B-cell hyperreactivity [9-11] with high relative numbers of IgG- and 
IgM-containing plasma cells [13-15], with rheumatoid factor and anti-La(SSB) specificity 
[9,12]. In agreement with this, it was reported that the group of SS patients with antì-
La(SSB) in serum had a significantly greater numerical density of immunoglobulin-
containing plasma cells in LSG biopsies than the group of SS patients without detectable 
anti-La(SSB) in serum [31]. 
Recently, we found a 45% prevalence of a grade IV lymphocytic adenitis in the 
LSGs of patients with rheumatoid arthritis without any clinical suspicion of SS or 
immunohistologic abnormalities, defined by DF-score <-2 and/or %IgA-containing 
plasma cells <70 [31,32]. Although RA patients with a grade IV adenitis should be 
diagnosed as secondary SS according to the criteria of Daniels and Talal [18], it seemed 
unlikely that our RA patients suffered from SS due to the absence of specific 
immunohistologic features of primary and secondary SS in the LSG biopsy. Based on the 
highly increased prevalence of a grade IV adenitis in RA patients, as compared to the 
5%-10% prevalence in the normal population it was concluded that focal lymphocytic 
adenitis of LSGs is related to RA as an extra-articular phenomenon, but is based on 
another pathophysiologic mechanism than the same type of adenitis in primary and 
secondary SS [31]. Our observation of normal La(SSB) immunoreactivity pattern in the 
LSGs of RA patients with a grade IV adenitis, but without clinical suspicion of SS and 
without the aforementioned immunohistologic abnormalities in plasma cell composition, 
gives further support for the hypothesis of different pathogenetic mechanisms. 
Although the cause of the aberrant La(SSB) immunoreactivity pattern in acinic 
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cells in SS patients remains to be established, it seems likely that the nuclear 
accumulation and redistribution of La(SSB) in the acinic cells plays a role in the 
pathogenesis of the B-cell hyperreactivity and chronic lymphocytic adenitis of the salivary 
glands of SS patients. In addition, immunohistologic examination of the immunoreactivity 
pattern of La(SSB) in acinic cells seems to be a simple and promising tool to improve the 
diagnostic possibilities of the LSG biopsy. 
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Abstract 
Three patients are presented to illustrate the diagnostic and prognostic value of 
quantitative immunohistological examination of labial salivary gland biopsy in 
Sjogren's syndrome. In àn obvious case of primary Sjogren's syndrome and in a 
case of rheumatoid arthritis without clinical and serological evidence of secondary 
Sjogren's syndrome.quantitative immunohistological examination of the labial 
salivary gland biopsy gave more appropriate information than the widely accepted 
lymphocytic focus score criterion for Sjogren's syndrome. In the third case 
quantitative immunohistological examination disclosed monoclonal B-cell expansion 
in the labial salivary gland biopsy six months before evidence of systemic 
monoclonal ganunopathy appeared. 
Introduction 
Sjogren's syndrome (SS) is a systemic autoimmune disease which affects 
exocrine glands and is clinically characterized by keratoconjunctivitis sicca (KCS) and 
xerostomia [1]. A common finding in SS patients is polyclonal B-cell activation, 
characterized by hypergammaglobulinemia and autoantibody formation [2]. In some SS 
patients the disease evolves into a benign or malignant monoclonal process [3]. 
A lymphocytic focus score (LFS) of > 1 lymphocytic focus (collection of 50 or 
more lymphocytes and histiocytes) per 4 mm2 of labial salivary gland (LSG) tissue, is a 
widely accepted criterion for the confirmation of SS [4,5]. Other salivary gland tests such 
as sialography, sialometry and sialoscintigraphy are both nonspecific and nonsensitive 
[6]. However, an LFS > 1 has not been encountered in up to 74% of patients clinically 
diagnosed as having SS [7-9]. Furthermore in 6-9% of individuals of the normal 
population a focus score >1 is found in the LSG biopsy [10,11]. Although SS can be 
seen in association with other connective tissue diseases, an LFS > 1 has been observed 
in patients with connective-tissue diseases without evidence of SS [12]. For these reasons 
the value of LSG biopsy has been questioned and it has even been proposed to abandon 
LSG biopsy in SS [8,12]. 
Recently, a quantitative immunohistological (QIH) criterion for confirmation of 
SS in the LSG biopsy has been described by our group [13]. The criterion is based on 
the percentages IgA- (%IgA) and IgG- (%IgG) containing plasma cells in the LSG 
biopsy, which are used in a discriminant function, DF = 0.062 χ %IgA - 0.088 χ %IgG 
- 4.387. A diagnosis of SS can be made when DF is smaller than -1.19. The QIH 
criterion was shown to be highly sensitive and specific [13]. In the present study three 
patients are presented to illustrate the diagnostic and prognostic value of QIH 
examination of LSG biopsy in SS. 
82 
Case reports 
Patient A. A 44-yr-old man presented with parotid gland swelling, oral dryness 
and burning eyes. He had a history of recurrent spontanously disappearing parotid gland 
swelling and 11 and 7 yr earlier benign lymphoepithelial lesions from his palatal minor 
salivary glands had been removed. 
Ophthalmologic examination revealed KCS. The laboratory results were (normal 
values in parentheses): gammaglobulin 21 g/1 (8.5-14.7 g/1), IgG 21.9 g/1 (10.4-14.6 
g/1), IgA 3.09 g/1 (1.4-2.6 g/1), IgM 2.08 g/I (0.7-1.5 g/1), Rose-Waaler 1:256, 
antinuclear antibodies 1:320, and positive anti SS-B. 
Histological examination of an LSG biopsy showed a diffuse lymphoplasmacytic 
infiltrate without lymphocytic foci. Furthermore a moderate atrophy of acini and a local 
hyperplasia of intralobular ducts with ductectasia was observed. Thus, although the LFS 
criterion did not confirm the diagnosis of SS, the clinical and serological findings and the 
histological findings in the palatal salivary glands were so characteristic that the diagnosis 
primary SS was beyond any doubt. 
Patient B. A 57-yr-old woman with an 11-yr history of rheumatoid arthritis 
without sicca complaints gave informed consent for LSG biopsy. An LFS of 2.1 was 
found in the LSG biopsy. However, ophthalmologically no signs of KCS could be 
detected. Serological examination at the time of LSG biopsy revealed no rheumatoid 
factor or antinuclear antibodies. Serum gammaglobulin was normal. Thus, although an 
LFS > 1 was found in the LSG biopsy of this patient with rheumatoid arthritis, the 
diagnosis of secondary SS could not be confirmed by any other findings. 
Patient C. A 74-yr-old woman presented with dry eyes and dry mouth. She had 
a history of Raynaud's phenomenon, systemic vasculitis, mixed cryoglobulinemia (type 
III) and mesangiocapillary glomerulonephritis. Histological examination of an LSG biopsy 
revealed extensive lymphoplasmacytic infiltration with an LFS of 8.4. The laboratory 
results were (normal values above): gammaglobulin 10.4 g/1, IgG 7.0 g/1, IgM 4.02 g/1, 
IgA 1.53 g/1, antinuclear antibody 1:2430, and positive anti-SSB. LE cells and anti-
dsDNA were not encountered. Serum immunoelectrophoresis at the time of LSG biopsy 
did not show paraproteins. Ophthalmologic examination revealed KCS. 
Six months later monoclonal IgM/k paraprotein appeared in the serum. 
Methods 
Inununohlstology. The LSG biopsies from patient А, В and С were fixed in 
formol sublimate [14] and embedded in paraffin. Intracellular immunoglobulin heavy 
(alpha, gamma and mu) and light chains (kappa (k) and lambda (1)) were demonstrated in 
5μτη serial sections by Stemberger's unlabelled peroxidase anti-peroxidase procedure [15] 
(Table 1). A sequential double immunofluoresence labelling procedure [16] using 
polyclonal antibodies from different species against heavy and light chains (viz. IgA/k, 
IgA/1, IgG/k, IgG/1, IgM/k and IgM/1) was performed on 5μΐη serial parafñn sections in 
order to detect monoclonal proliferations. AU antisera were obtained from Dakopatts, 
Denmark. Specificity and control tests were performed adequately [13,16]. 
Quantification procedure. IgA-, IgG-, IgM-, k-, and 1-positive plasma cells 
were counted with a semi-automatic image-analysis system (MOP Videoplan, Kontron, 
Munich) in 30-50 systematically sampled test fìelds of 0.04 mm2 LSG tissue at a 
magnification of x500. The percentages of IgA-, IgG- and IgM-containing plasma cells 
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TABLE 1 
Peroxidase anti-peroxidase procedure. 
1 Dewaxing and rehydration 
2 Removing of mercury pigment by immersion in lugol's 
iodine (5 mm) 
3. Blocking of endogenous peroxidase in methanol containing 
1 % hydrogen peroxide (30 mm) 
4. Preincubation with normal swine semm (20 nun) 
5 Incubation with diluted monospecific anlisera against IgA 
(1/800), IgG (1/200) and IgM (1/800) (1 h) 
6 Incubation with diluted swine anti-rabbit semm (1/20) (30 
min) 
7 Incubation with diluted rabbit PAP complex (1/800) (20 
nun) 
8 Development of peroxidase with diaminobenzidine and hy­
drogen peroxide (S mm), intensified with CuSO« (1 nun) 
9 Counterstam with Mayer's hacmatoxybn, dehydrate and 
mount in DPX 
Antisera were diluted in phosphate-buffered sahne (pH 7 4) 
containing 1% bovine serum albumin, all incubations at room 
temperature 
and the k/1 ratios were determined. The percentages of IgA- and IgG-containing plasma 
cells were used to calculate the DF-scores [13] by substituting these percentages in the 
discriminant function DF = 0.062 χ %IgA - 0.088 χ %IgG - 4.387. The diagnosis SS is 
made if DF < -1.19 [13]. 
Results 
Table 2 shows the results of QIH examination of the LSG biopsies from patient 
А, В and С Patient A and patient С had DF-scores < -1.19, indicating SS [13], 
whereas patient В had a DF-score > -1.19. The k/1 ratios from patient A and patient В 
were normal (normal range 0.97-3.19) [17]. In patient С 85% of the plasma cells in the 
LSG biopsy were IgM-containing with a k/1 ratio of 10.3. Double immunofluorescence 
labelling on paraffin sections revealed monoclonal IgM/k in patient С (Fig.l); the 
plasmacytic infiltrates of patient A and В were polyclonal. 
Discussion 
The present study shows that only focal lymphocytic sialadenitis of the LSG 
tissue is not justified as a diagnostic criterion for SS in the LSG biopsy. In patient A, an 
obvious case of primary SS, histological examination of the LSG biopsy gave a non-
confirmatory result when the LFS criterion was applied. However, QIH examination of 
the LSG biopsy was consistent with the diagnosis of SS. Patient B, with rheumatoid 
arthritis, would have been diagnosed as having SS if the LFS criterion had been applied. 
However, QIH examination did not reveal evidence of SS, nor were any clinical signs of 
SS found in this patient. 
In a recent study by Speight et al. [18] DF-scores < -1.19 were found in 9/9 of 
patients with rheumatoid arthritis and secondary SS. In addition, Matthews et al. [19] 
studied non-SS patients with rheumatoid arthritis. Comparison of the results of Matthews 
et al. [19] with those of Speight et al. [18] (Table 3) revealed that the distribution pattern 
of Ig-containing plasma cells in LSG tissue from non-SS patients with rheumatoid 
TABLE 2 
Results of QIH examination of the LSG 
biopsies. 
Patient 
A 
В 
С 
IgA 
(%) 
67.0 
86.4 
7.0 
IgG 
(%) 
27.0 
9.5 
8.0 
IgM 
(«) 
6.0 
4.1 
85.0 
DF 
-2.60 
013 
-4.70 
k/1 
1.2 
1.4 
10.3 
%IgA, %IgG and %IgM = percentages of 
IgA-, IgG- and IgM-containing plasma cells; 
DF = DF-score; k/1 = k/1 ratio. 
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Fig. 1 Immunohistological findings in labial salivary gland biopsy specimen from patient C: double immunofluorescence labelling of 
IgM with fluorescein (FITC) (A) and kappa with rhodarrane (TRITC) (B) in one section, and IgM with FITC (C) and lambda with 
TRITC (D) in a consecutive section In the first section (A and B) large numbers of IgM/kappa containing plasma cells are present, 
With double immunofluorescence labelling for IgM and lambda (C and D) all IgM-containmg plasma cells are negative for lambda; 
D sporadically lambda positive plasma cells are encountered (arrow). 
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Fig. 1 (continued). 
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TABLE 3 
The percentages of IgA-, IgG- and IgM-containing plasma cells in labial salivary gland tissue of 
patients with rheumatoid arthritis (RA) or Sjogren's syndrome (SS). 
LSG biopsy group 
RA pauents * 
(
Л
= 1 0 ) 
SS patients '' 
(л = П) 
Two-lailed Ρ 
IgA 
(*) 
80 5 ±16.0 
38 3 ±18.4 
< 0.0001 
IgG 
(%) 
8 8 ± 6 1 
34.9 ±21.3 
0.001 
IgM 
(») 
10.7 ±12 1 
26 8 ±15 5 
0 02 
' Patients studied by Matthews et al. [19]; b patients studied by Speight et al. [18]: 9 patients with 
RA and secondary SS and 2 patients with primary SS; two tailed Ρ values obtained from 
Student's t-test. 
arthritis differed markedly from that of patients with rheumatoid arthritis with secondary 
SS. It is unlikely that this dramatic difference (Table 3) is caused by the two primary SS 
patients who were included in the study by Speight et al. [18]. 
We found focal lymhocytic infiltrates with lymphocytic focus scores > 1 in 5/11 
patients with rheumatoid arthritis clinically not suspected of having SS who volunteerd 
for LSG biopsy; only one had a DF-score < -1.19. In 4 patients with rheumatoid 
arthritis and secondary SS we found DF-scores < -1.19 (our unpublished observations). 
Thus alterations in the proportions of Ig-containing plasma cells in LSG tissue of SS 
patients seems to be a more disease specific feature than the bare presence of focal 
lymphocytic infiltrates. 
In patient C, with SS and severe extraglandular manifestations, QIH examination 
of the LSG tissue added important information. At the time of diagnosis there was a 
predominance of IgM/k-containing plasma cells in the LSG tissue, indicating monoclonal 
B-cell expansion, which was confirmed by double immunofluorescence. Not until after 
six months did serum Immunoelectrophoresis revealed monoclonal IgM/k. It is likely that 
in this patient a generalization of the monoclonal process in the LSG tissue had taken 
place. Talal et al. reported macroglobulin systhesis in LSG tissue from an SS patient with 
coexisting primary (Waldenström-type) macroglobulinemia [20]. In a study by Lane et al. 
[21] one SS patient had only lambda light chains in the LSG biopsy, suggesting a 
monoclonal process, however, without serological confirmation of monoclonal 
gammopathy. More recently, it was shown that SS patients with monoclonal IgM/k 
cryoglobulinemia and with malignant lymphoma exhibit monoclonal B-cell expansion in 
the LSG tissue, defined by a k/1 ratio > 3 [22]. Thus determination of k/1 ratios in LSG 
biopsies from SS patients may provide prognostic information with regard to the 
transformation to systemic monoclonal gammopathies. As far as we are aware, patient С 
is the first SS patient in whom such a transformation has been reported. 
We conclude that LSG biopsy should be maintained as an important tool for 
diagnosis of SS and that QIH examination of LSG biopsies is a necessity. 
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Abstract 
A 45 year old man, previously diagnosed as having sarcoidosis, presented with signs 
and symptoms of a pancreatic malignancy. An explorative laparotomy, however, 
showed only chronic pancreatitis. He was found to have a raised erythrocyte 
sedimentation rate, normocytic normochromic anaemia, renal insufficiency, 
hypergammaglobulinaemia, and a strongly positive rheumatoid factor and 
antinuclear antibody titré. Bilateral hilar lymph node enlargement was noted on 
chest χ ray. Subsequently, the patient complained of xerostomia and 
keratoconjunctivitis sicca. Large lymphocytic infiltrates and a shift in the relative 
number of IgA bearing plasma cells were seen in tissue obtained by sublabial 
salivary gland biopsy. A transbronchial lung biopsy and review of the biopsies of the 
pancreas, the lung, liver, and a lymphnode all failed to show granulomatous disease. 
These findings strongly suggested a diagnosis Sjogren's syndrome instead of 
sarcoidosis. This case shows the difficulty sometimes encountered in differentiating 
between sarcoid and systemic Sjogren's syndrome, and the value of a sublabial 
salivary gland biopsy. 
Primary Sjogren's syndrome is a chronic inflammatory autoimmune disorder, 
which may present as the sicca complex only, but may also affect many organs. 
Sarcoidosis can mimic the clinical symptoms of Sjogren's syndrome and differential 
diagnosis between these disorders clinically and histologically may be difficult [1]. 
Recently, Melsom et al reported a patient presenting with clinical and histological 
features of Sjogren's syndrome, who seemed to have sarcoidosis [2]. 
We present a patient with sarcoidosis, who underwent an exploratory laparotomy 
for a suspected malignancy. Microscopic examination of biopsy specimens of the lung, 
liver, pancreas, and sublabial salivary gland showed no granuloma formation. The 
findings in the sublabial salivary gland strongly suggested a diagnosis of Sjogren's 
syndrome. 
Case report 
In July 1986 a 45 year old man was referred to the department of internal medicine by 
the department of surgery. He had undergone a diagnostic laparotomy because of a 
suspected pancreatic malignancy. An enlargement of the pancreatic head was found. 
Microscopic examination of the pancreas showed only extensive fibrosis and a diffuse 
mononuclear infiltrate, compatible with a diagnosis of chronic pancreatitis. There were 
no signs of a malignancy in the pancreas or the associated lymph node. 
The patient complained of extreme tiredness, a dry mouth, and dysphagia and 
difficulty in chewing. The submandibulary salivary glands seemed to be enlarged, and six 
months previously he had consulted an ophthalmologist for dry eyes. There was no 
arthralgia, anorexia, or weight loss. He had had Raynaud's phenomenon. 
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One year previously he had attended his local hospital because of tiredness. An χ 
ray of the chest had shown bilateral hilar lymph node enlargement and as sarcoidosis was 
suspected a transbronchial lung biopsy had been performed. Microscopic examination of 
these biopsy specimens had shown epitheloid cells and a few granulomatous structures. 
Therefore it was concluded that the patient had sarcoidosis. A few months later he again 
attended his local hospital because of pain in the right upper abdominal quadrant. 
Biochemical examination showed raised values for alkaline phosphatase 390 (normal 
<125)) gamma-glutamyltransferase 519 (normal <30), S-alanine aminotransferase 91 
U/l (normal <25), and S-aspartate aminotransferase 262 U/l (normal <25). A liver 
biopsy specimen showed small infiltrates of granulocytes and lymphocytes but no 
evidence of granulomatous disease. An endoscopic retrograde cholangiopancreatography 
was performed, showing narrowing of the pancreatic and the common bile duct, raising 
suspicions of a tumour of the pancreas. Computed tomography showed an enlarged 
pancreatic head. At this point the patient was referred for explorative laparotomy. 
Physical examination at the department of general internal medicine showed a 
patient who looked anaemic with slightly enlarged, tender submandibulary glands, and a 
dry oral mucosa; otherwise the findings were unremarkable. There was no hepatomegaly, 
splenomegaly, or lymph node enlargement. 
Laboratory investigations showed raised erythrocyte sedimentation rate (ESS) 
(112 mm/h), a normochromic, normocytic anaemia with a haemoglobin 106 g/1 (normal 
130-160). The other haematological indices were normal. The gammaglobulins were 25 
g/1 (normal 7-15). Serum Immunoelectrophoresis showed a hypergammaglobulinaemia 
and no paraprotein. No cryoglobulins were found. Serological tests for rheumatoid 
factor, the antinuclear antibody test, and circulating immune complexes were strongly 
positive. Anti-SS-A and anti-SS-B were not detected. Serum creatinine was slightly raised 
(166 μΐηοΐ/ΐ) (normal 60-100) and there was a proteinuria of 0.82 g/1. Tests for liver 
function, serum amylase, and calcium were normal. Angiotensin converting enzyme 
concentration was increased 20.2 mE/ml (normal 12-15). A Schirmer test (right 6 mm, 
left 8 mm) showed diminished tear production. Rose bengal staining of the conjunctiva 
was positive. Routine chest χ rays showed diffuse fibrotic lesions and bilateral hilar 
enlargement, the latter confirmed by tomography. Submandibulary gland sialography was 
performed, showing diffuse narrowing and widening of the ducts, suggesting chronic 
inflammation. 
As clinically the differential diagnosis lay between sarcoidosis and Sjogren's 
syndrome, fibreoptic bronchoscopy and sublabial salivary gland biopsy were carried out. 
Fibrosis and an infiltration of histiocytes and lymphocytes was found in the lung biopsy 
specimen (Fig 1) but no granulomata, multinucleate giant cells, or epitheloid cells were 
seen. Microscopy of the sublabial salivary gland biopsy specimen (Fig 2) showed large 
focal lymphocytic infiltrations (focus score 2.5 with confluent foci) and ductal 
hyperplasia. No granulomata or multinucleate giant cells were found. Immunohistological 
staining showed a polyclonal plasmacytic infiltrate and a shift in the relative number of 
IgA-containing plasma cells in favour of IgG- and IgM- containing plasma cells. The 
plasmacytic infiltrate consisted of 40.1% IgA-containing plasma cells (normal (SD) 91.1 
(8.6)%, 47.1% IgG-containing plasma cells (normal 3.4 (4.8)%), and 12.8% IgM-
containing plasma cells (normal 4.8 (4.8)%) [3]. both the histological and the 
immunohistological findings in the sublabial salivary gland biopsy specimen were 
strongly suggestive of Sjogren's syndrome. When revision of the early lung biopsy was 
performed a non-specific fibrosing inflammatory process was found. Some structures 
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Fig. 1. Part of the second lung biopsy specimen with fibrosis and some mononuclear 
inflammatory cells. No evidence of non-caseating granulomatous process. (Haematoxylin and 
eosin) 
Fig. 2. Labial salivary gland biopsy specimen with large confluent lymphocytic foci and 
destruction of parenchyma. (Haematoxylin and eosin) 
Fig. 3. Part of the first lung biopsy specimen with fibrosis and diffuse infiltration with 
mononuclear inflammatory cells. No evidence of non-caseating granulomatous process. 
(Haematoxylin and eosin) 
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were suggestive of sarcoidosis, but no granulomata, epitheloid cells, or multinucleate 
giant cells could be shown (Fig 3). 
Discussion 
Primary Sjogren's syndrome is a chronic inflammatory disorder characterized by 
lymphoid cell infiltration and destruction of salivary and lachrymal glands, resulting in 
keratoconjunctivitis sicca and xerostomia. Sarcoidosis may present with 
keratoconjunctivitis sicca and sialoadenitis resembling Sjogren's syndrome [4]. In 
addition, the pulmonary manifestations of Sjogren's syndrome may resemble those of 
sarcoidosis [5,6]. Bilateral hilar lymph node enlargement strongly suggested sarcoidosis 
in our patient, and this diagnosis was supported by the general symptoms and the raised 
angiotensin converting enzyme concentration in the plasma. 
The clinical diagnosis of primary Sjogren's syndrome was supported by the 
typical ocular and salivary symptoms, the sialoadenitis seen on sialography, and the 
biochemical indices, including raised ESR, gammaglobulin value, and the positive 
rheumatoid factor and antinuclear antibody test [7]. Antibodies to SS-Α and SS-B were 
negative, but although often found in Sjogren's syndrome, they are not always present 
[8]. Furthermore, the patient had chronic pancreatitis, proteinuria, and raised serum 
creatinine, which have been reported in primary Sjogren's syndrome [7,9,10]. Thus as 
none of these findings is specific a diagnosis on clinical grounds was not possible. 
Therefore, a sublabial salivary gland biopsy and a second lung biopsy were 
carried out to differentiate between sarcoidosis and Sjogren's syndrome. Furthermore, 
when the previous transbronchial lung biopsy specimen was reviewed, no definite 
granulomata, multinucleate giant cells, or epitheloid cells could be shown, but fibrosis 
and infiltrations of histiocytes and lymphocytes were present. The first biopsy specimen 
did, however, show some structures faintly resembling granulomata such as may be 
found in sarcoidosis. 
The histological and immunohistological findings in the sublabial salivary gland 
biopsy specimen strongly indicated Sjogren's syndrome [3,11,12]. The absence of 
granulomata was also against a diagnosis of sarcoidosis. 
Non-specific infiltrations by mononuclear cells and fibrosis in the biopsy 
specimens of the liver, lymph node, and pancreas as seen in this case have been often 
reported in primary Sjogren's symdrome [7], and as no granulomata could be shown in 
these biopsy specimens the diagnosis of primary Sjogren's syndrome was supported 
indirectly. 
In conclusion, this case report shows (a) the severe systemic manifestations, 
including involvement of the lung, pancreas, and (probably) the kidney, which may occur 
in primary Sjogren's syndrome; (b) how difficult differential diagnosis from sarcoidosis 
can be; and (c) that a sublabial salivary gland biopsy may be helpful for the diagnosis. 
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Summary 
Histopathology of the labial salivary gland (LSG) biopsy is considered the most disease 
specific single test in the diagnosis of Sjogren's syndrome (SS). However, no agreement 
has been obtained up to now on the interpretation of the histopathologic findings in the 
LSG biopsy. A grade IV focal lymphocytic adenitis, which corresponds with the presence 
of more than 1 lymphocytic focus per 4 mm1 LSG tissue (lymphocytic focus score 
greater than 1), is considered necessary for confirmation of the diagnosis of SS by 
various investigators. However, this criterion results in high rates of false positive and 
false negative diagnoses. 
In chapter 1 a review of the literature with regard to SS diagnosis is given, and 
in particular the value of LSG biopsy. A new and very promising diagnostic criterion for 
SS, based on the percentages of Ig A- and IgG-containing plasma cells in the LSG biopsy 
has been described recently. 
The aim of the study, described in this thesis, was to further investigate the 
possibilities of quantitative immunohistologic examination of LSG biopsies, with 
emphasis on diagnosis, prognosis, and pathogenesis of Sjogren's syndrome. 
In chapter 2 the effects of tissue fixation and immunohistologic staining 
technique on the results quantitative immunohistologic (QIH) examination of the plasma 
cellular infiltrate in salivary gland tissue were studied. Lamellated submandibular salivary 
gland tissue was alternately fixed in a 4% buffered formol solution or a formol sublimate 
solution. Tissue sections were stained with an indirect immunoperoxidase or a peroxidase 
anti-peroxidase (PAP) technique, and plasma cells were enumerated by 3 independent 
observers. Relative numbers of Ig-containing plasma cells appeared to be less sensitive 
for systematic errors due to tissue fixation and immunohistologic staining procedure than 
absolute numbers of Ig-containing plasma cells. The best inter-observer reproducibility of 
plasma cell counts was obtained in sections from formol sublimate fixed specimens 
stained according to the PAP procedure. This combination of tissue fixation and staining 
procedure was subsequently used in the other studies, described in this thesis. 
In chapter 3, a QIH examination was performed on LSGs of 80 healthy controls, 
46 patients with SS, 5 patients with "probable SS", 36 patients with keratoconjunctivitis 
sicca (KCS) with a lymphocytic focus score < 1 in the LSG biopsy, and 18 patients with 
rheumatoid arthritis clinically not suspected for SS. A criterion based on percentages of 
IgA- and IgG-containing plasma cells [Discriminant function (DF) = 0.062 χ %IgA -
0.088 χ %IgG - 4.387; the diagnosis of SS is reached if DF < -2] gave the best classifi­
cation results (specificity 98.8%, sensitivity 97.5%). A criterion based on the percentage 
of IgA-containing plasma cells (the diagnosis of SS is reached if %IgA < 70) had a 
specificity of 98.8% and a sensitivity of 95.0%. The interobserver reproducibility of QIH 
diagnoses was 97%, and quantification of plasma cells could be performed accurately by 
technicians. This study has shown for the first time that QIH criteria for SS are able to 
1) conform the diagnosis SS in LSG biopsies of patients with KCS in the absence of a 
grade IV focal lymphocytic adenitis; and 2) distinguish between a grade IV focal 
lymphocytic adenitis in the LSGs of SS patients and rheumatoid arthritis patients without 
SS. This study shows that QIH criteria are more sensitive and disease specific than the 
widely accepted grade IV lymphocytic adenitis, which corresponds with a lymphocytic 
focus score > 1, and these criteria should be included in the international criteria for SS. 
In chapter 4 QIH examination was performed on LSGs of 45 patients with SS, 
18 rheumatoid arthritis patients without SS and 80 healthy controls has been performed. 
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Monotypic plasma cell populations, defined by a kappa/lambda ratio ¿ 3 , were only 
observed in the older SS patients ( > 4 3 years). In almost all these patients monotypic 
plasma cell populations were present in multiple LSGs and the IgM/kappa monotypia was 
observed most frequently. In none of the SS patients there was evidence of systemic 
monoclonal lymphoproliferative disease at the time of LSG biopsy. The prevalence of 
monotypic plasma cell populations in our SS group was 22% (10/45) and there was no 
statistically significant predilection for primary SS. Of special clinical interest is our 
observation that progression into systemic monoclonal lymphoproliferative disease had, at 
present, exclusively occurred in this subgroup of SS patients with a prevalence of 30% 
(3/10). Thus, a subgroup of SS patients exists with monotypic plasma cell populations in 
their LSG tissue. Patients in this subgroup seem to be prone to the development of 
systemic lymphoproliferative disease. 
In chapter S the immunoreactivity pattern of the La/SS-B antigen was 
investigated in LSG'biopsies of subjects with and without SS using a mouse monoclonal 
antibody against the La/SS-B antigen. The immunoreactivity pattern of the La/SS-B 
antigen was also studied in normal tissues obtained at autopsy within two hours after 
death. Patients with SS showed a dramatic accumulation of the La/SS-B antigen in the 
nuclei of acinic cells of salivary glands compared to non-SS patients. In SS patients 
La/SS-B antigen was also detected in the cytoplasm as a perinuclear or diffuse staining, 
sometimes it was found along the cell membrane as well. This aberrant immunoreactivity 
pattern of La/SS-B correlated very well with QIH abnormalities in the LSG tissue, but 
not with a lymphocytic focus score greater than one. A normal immunoreactivity pattern 
of La/SS-B in LSG tissue of patients with rheumatoid arthritis and a lymphocytic focus 
score greater than one supports the suggestion made in chapter 3, that the focal 
lymphocytic adenitis of LSGs in rheumatoid arthritis is based on another pathogenetic 
mechanism than that occurring in SS. The aberrant immunoreactivity pattern of La/SS-B 
in LSGs of SS patients supports the model that the La/SS-B antigen itself can invoke a 
local antigen driven immune response. An aberrant immunoreactivity pattern of La/SS-B 
in LSG tissue of SS patients may also be a useful marker in the diagnosis of this 
disease. 
In chapter 6 the possibilities of QIH examination in clinical practice are 
illustrated by 3 case reports. Chapter 7 describes the difficulties which can be 
encountered in the differentiation between SS and sarcoidosis, and the value of LSG 
biopsy in such cases. 
Conclusions 
In the diagnosis of SS, it is necessary to take a LSG biopsy. With the relatively non-
traumatic horizontal incision procedure, at least three minor salivary glands should be 
obtained. To visualize Ig A-, IgG-, and IgM-, kappa-, and lambda-containing plasma 
cells, the biopsy specimen should de be fixed in a formol sublimate solution and 5 μιπ 
serial sections should be stained with a peroxidase anti-peroxidase technique. SS can be 
diagnosed if the DF score is < -2 or the percentage of IgA-containing plasma cells is 
< 7 0 . A kappa/lambda ratio > 3 in the plasma cellular infiltrate may indicate an 
increased relative risk of developing systemic monoclonal lymphoproliferative disease. 
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Samenvatting 
Histopathologisch onderzoek van het lipbiopt wordt door velen beschouwd als de meest 
ziektespecifieke test bij de diagnostiek van het Sjogren's syndroom. Er bestaat echter nog 
geen eenstemmigheid over de interpretatie van de histopathologische bevindingen. Een 
graad IV focale lymfocytaire adenitis, hetgeen overeenkomt met de aanwezigheid van 
meer dan 1 lymfocytair focus per 4 mm2 labiaal speekselklierweefsel (focus score groter 
dan 1), wordt door velen als norm gehanteerd. Dit criterium resulteert echter in hoge 
aantallen fout positieve en fout negatieve diagnoses. 
In hoofdstuk 1 wordt een overzicht van de literatuur gegeven met betrekking tot 
de Sjogren's syndroom diagnostiek, en in het bijzonder de betekenis van het lipbiopt. Een 
nieuw en veelbelovend diagnostisch criterium voor Sjogren's syndroom met hoge 
specificiteit en sensitiviteit, gebaseerd op de percentages IgA- en IgG-bevattende plasma 
cellen in het lipbiopt werd recent beschreven. 
De studie, beschreven in dit proefschrift, had tot doel de mogelijkheden van 
kwantitatief immunohistologisch onderzoek van lipbiopten verder te onderzoeken, waarbij 
de nadruk lag op diagnostiek, prognose en Pathogenese van het Sjogren's syndroom. 
In hoofdstuk 2 zijn de effecten van weefselfixatie en immunohistologische 
kleurtechniek op het kwantificeren van plasmacellulaire infiltraten in speekselklier 
weefsel bestudeerd. Gelamelleerd submandibulair speekselklierweefsel werd om en om 
gefixeerd in een 4% gebufferde formaline oplossing of een sublimaatformaline oplossing. 
Weefselcoupes werden gekleurd met een indirecte immunoperoxidase of een peroxidase 
anti-peroxidase (PAP) techniek en plasmacellen werden gekwantificeerd door 3 
onafhankelijke onderzoekers. Relatieve aantallen Immunoglobuline (Ig)-bevattende plasma 
cellen bleken minder beïnvloed te zijn te zijn door systematische fouten ten gevolge van 
weefselfixatie en immunohistologische kleurtechniek dan absolute aantallen Ig-bevattende 
plasma cellen. De beste reproduceerbaarheid tussen verschillende onderzoekers werd 
verkregen in coupes van sublimaatformaline gefixeerd weefsel gekleurd volgens de PAP 
techniek. Deze combinatie van weefsel fixatie en kleurtechniek werd vervolgens gebruikt 
in de andere kwantitatief immunohistologische studies, beschreven in dit proefschrift. 
In hoofdstuk 3 werd kwantitatief immunohistologisch onderzoek toegepast op 
lipbiopten van 80 gezonde individuen, 46 patiënten met het Sjogren's syndroom, S 
patiënten met "waarschijnlijk Sjogren's syndroom", 36 patiënten met keratoconjunctivitis 
sicca (KCS) met een lymfocytaire focus score kleiner dan 1 in het lipbiopt en 18 
patiënten met reumatoide arthritis zonder klinisch bewijs voor het Sjogren's syndroom. 
Een criterium gebaseerd op percentages IgA- en IgG-bevattende plasma cellen 
[discriminant functie (DF) = 0.062 χ %IgA - 0.088 χ %IgG - 4.387; de diagnose 
Sjogren's syndroom wordt gesteld bij DF kleiner dan -2] gaf de beste classificatie 
resultaten (specificiteit 98.8%, sensitiviteit 97.5%). Een criterium gebaseerd op het 
percentage IgA-bevattende plasma cellen (de diagnose Sjogren's syndroom wordt gesteld 
bij een percentage IgA-bevattende plasma cellen kleiner dan 70) had een specificiteit van 
98.8% en een sensitiviteit van 95.0%. De reproduceerbaarheid van dit kwantitatief 
immunohistologisch onderzoek was tussen verschillende onderzoekers 97%; 
kwantificering van plasmacellen kon accuraat worden uitgevoerd door analisten. In deze 
studie is voor het eerst aangetoond dat het met behulp van kwantitatief 
immunohistologisch onderzoek mogelijk is om 1) de diagnose Sjogren's syndroom te 
bevestigen in lipbiopten van patiënten met KCS zonder een graad IV focale lymfocytaire 
adenitis; en 2) onderscheid te maken tussen een graad IV focale lymfocytaire adenitis in 
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labiale speekselklieren van patiënten met Sjogren's syndroom en van patiënten met 
reumatoide arthntis zonder Sjogren's syndroom. Deze studie toont aan dat kwantitatief 
immunohistologische criteria een hogere sensitiviteit en ziekte specificiteit hebben dan het 
veel gebruikte graad IV lymfocytaire adenitis criterium, hetgeen overeen komt met een 
lymfocytaire focus score groter dan 1. Het wordt aanbevolen deze criteria op te nemen in 
de internationale diagnostische criteria voor het Sjogren's syndroom. 
In hoofdstuk 4 is kwantitatief immunohistologisch onderzoek verricht op labiale 
speekselklieren van 45 patiënten met het Sjogren's syndroom, 18 patiënten met 
reumatoide arthritis zonder Sjogren's syndroom en 80 gezonde individuen. Monotypische 
plasma cellen, gedefinieerd door een kappa/lambda ratio ^ 3, werden slechts gezien bij 
de oudere Sjogren's syndroom patiënten (>43 jaar). Bij nagenoeg alle patiënten waren 
de monotypische plasma cellen aanwezig in multipele labiale speekselklieren en 
IgM/kappa monotypie werd het meest gezien. Bij geen van de Sjogren's syndroom 
patiënten waren er aanwijzingen voor een systemische lymfoproliferatieve aandoening op 
het tijdstip dat lipbiopt werd genomen. De prevalentie van monotypische plasma cel 
populaties in onze Sjogren's syndroom patiënten groep was 22% (10/45); er was geen 
statistisch significante voorkeur voor primair Sjogren's syndroom. Van klinisch belang is 
onze observatie dat progressie naar systemische lymfoproliferatieve aandoeningen tot op 
heden alleen in deze subgroep is opgetreden met een prevalentie van 30% (3/10). Er 
bestaat dus een subgroep van Sjogren's syndroom patiënten met monotypische plasma cel 
populaties in hun labiale speekselklierweefsel. Patiënten in deze subgroep lijken een 
verhoogd relatief risico te hebben om systemische lymfoproliferatieve aandoeningen te 
ontwikkelen. 
In hoofdstuk 5 is het patroon van het La(SSB) antigeen bestudeerd in lipbiopten 
van individuen met en zonder het Sjogren's syndroom, waarbij gebruik werd gemaakt 
van een muizen monoclonaal antilichaam gericht tegen het La(SSB) antigeen. Het patroon 
van het La(SSB) antigeen werd ook bestudeerd in normale weefsels van obductie 
materiaal, binnen 2 uur postmortaal verkregen. Bij Sjogren's syndroom patiënten werd, 
in vergelijking met patiënten zonder het Sjogren's syndroom, een duidelijke accumulatie 
van het La(SSB) antigeen gezien in de nuclei van acinaire cellen van speekselklieren. Bij 
Sjogren's syndroom patiënten bleek het La(SSB) antigeen ook aanwezig in het cytoplasma 
als een perinucleaire of diffuse kleuring, soms werd het langs de cel membraan gezien. 
Dit afwijkende patroon van het La(SSB) antigeen correleerde zeer goed met kwantitatief 
immunohistologische afwijkingen in het labiale speekselklier weefsel, echter niet met een 
lymfocytaire focus score > 1 . Een normaal patroon van het La(SSB) antigeen in labiaal 
speekselklierweefsel van patiënten met reumatoide arthritis met een lymfocytaire focus 
score > 1 steunt de suggestie die in hoofdstuk 3 werd gedaan, namelijk dat de focale 
lymfocytaire adenitis van labiale speekselklieren bij reumatoide arthritis gebaseerd is op 
een ander pathogenetisch mechanisme dan dat van Sjogren's syndroom. Het afwijkende 
patroon van het La(SSB) antigeen in labiale speekselklieren van Sjogren's syndroom 
patiënten steunt de hypothese dat het La(SSB) antigeen zelf een lokale antigeen gedreven 
immuun reactie kan opwekken. Een afwijkend patroon van het La(SSB) antigeen in 
labiaal speekselklierweefsel van Sjogren's syndroom patiënten kan tevens als een 
diagnostische marker worden gebruikt. 
In hoofdstuk 6 worden de mogelijkheden van kwantitatief immunohistologisch 
onderzoek in de kliniek wordt geïllustreerd aan de hand van casuïstiek van 3 patiënten. 
Hoofdstuk 7 beschrijft de moeilijkheden die men kan tegenkomen bij de differentiatie 
tussen Sjogren's syndroom en sarcoidosis, en de waarde van lipbiopsie in zulke gevallen. 
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Conclusies 
In de diagnostiek van het Sjogren's syndroom mag een lipbiopsie niet ontbreken. Het 
verdient aanbeveling het biopt te nemen volgens de weinig traumatische horizontale 
incisie techniek, waarbij tenminste 3 speekselkliertjes dienen te worden verkregen. Om 
IgA-, IgG-, IgM-, kappa- en lambda- bevattende plasma cellen te visualiseren, wordt het 
weefsel gefixeerd in sublimaatformaline, en worden S μπι serie coupes gekleurd met een 
PAP techniek. De diagnose Sjogren's syndroom kan worden gesteld als de DF-score 
kleiner is dan -2 of het percentage IgA-bevattende plasma cellen kleinere is dan 70. Een 
kappa/lambda ratio ^ 3 in het plasmacellulaire infiltraat kan wijzen op een verhoogd 
relatief risico om een systemische monoclonale lymfoproliferatieve aandoening te 
ontwikkelen. 
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STELLINGEN 
I 
Bij de diagnostiek van het syndroom van Sjögren mag een lipbiopsie, uitgevoerd volgens de 
horizontale incisie techniek, niet ontbreken. 
Π 
De diagnose secundair syndroom van Sjögren bij patiënten met een reumatische aandoening kan 
niet gesteld worden op uitsluitend een graad IV lymfocytaire sialoadenitis van de labiale 
speekselklieren. 
Ш 
Door te spreken van "ziekte van Sjögren" in plaats van "syndroom van Sjögren" kan de 
spraakverwarring rond deze ziekte worden voorkomen. 
IV 
Het gebruik van obductiemateriaal om normaalwaarden van het aantal IgG-bevattende 
plasmacellen in weefsels te verkrijgen, moet ernstig ontraden worden. 
V 
Autoantilichamen gericht tegen nucleaire antigenen lijken zo goed als zeker geen rol te spelen in 
de Pathogenese van reumatische aandoeningen en derhalve verdient het aanbeveling meer aandacht 
te besteden aan de rol van de autoantigenen zelf. 
VI 
De DNA-ploidie status van een tumor zou uitsluitend bepaald moeten worden in de fractie 
tumorcellen die zich in de G,/G0-fase van de celcyclus bevinden. 
П 
Als reactie op de veranderende wetgeving aangaande de sociale zekerheid zou het aanbeveling 
verdienen nu reeds te beleggen in aandelen van verzekeringsmaatschappijen. 
Ш 
De opvatting dat in het begin van de culturele ontwikkeling van de mens slechts stilistische 
afbeeldingen werden vervaardigd en dat de naturalistische manier van afbeelden zich in een latere 
fase van de beschaving voordeed, lijkt op grond van recent archeologisch onderzoek niet langer 
houdbaar. 
IX 
Het beste advies aan een patiënt in Japan, lijdend aan het syndroom van Sjögren, is naar 
Californie te emigreren. 
Nijmegen, 17 maart 1993 C. Bodeutsch 

